All presenting authors of accepted abstracts will enjoy a special registration fee at RMB 1,000 for pre-registration on or before 4 January 2010 or RMB 1,400 for onsite registration. Click here to start registration!
| Presentation No. |
Submission No. |
Presenting Author |
Title |
| PP-001 |
SA00326 |
Liu Ying |
JAK1 gene polymorphisms are associated with the outcomes of hepatitis B virus infection but not with α interferon therapy response in Han Chinese population |
| PP-002 |
SA00383 |
Su Jong Yu |
Putative Association of DNA Methyltransferase 1 (DNMT1) Polymorphism with Risk of Human Hepatocellular Carcinoma among Chronic HBV Patients |
| PP-003 |
SA00452 |
Xiaomei Xu |
The Relationship Between HBeAg And HBV Persistent Infection |
| PP-004 |
SA00600 |
Hasmik Ghazinyan |
The Prevalence of Hepatitis B and C Virus Infection in Oncological Patients |
| PP-005 |
SA00969 |
HOU Zhouhua |
Retrospective analysis of 79 chronic severe hepatitis patients with invasive fungal infection |
| PP-006 |
SA00988 |
Eun Young Cho |
Epidermiological Study of Prognostic Factor in Occult Hepatitis B Virus Infection |
| PP-007 |
SA01461 |
Kui-xia Sun |
The Distribution of Hepatitis B Virus Genotypes and Sub-genotypes in China |
| PP-008 |
SA00063 |
Ching-Sheng Hsu |
Patients with Chronic Hepatitis B have Favorable Metabolic Profiles: A Case-Control Study |
| PP-009 |
SA00085 |
Zhonghua Lu |
Five years follow-up study of 220 chronic HBV carriers |
| PP-010 |
SA00110 |
Karen Batoctoy |
HBV/A and HBV/C Genotype Predominance among Patients with Hepatitis B virus Infection in Cebu City, Philippines |
| PP-011 |
SA00126 |
Shahinul Alam |
Lifetime Exposure Rate Of Hepatitis B Virus In A Rural Area Of Bangladesh And Possible Route Of Transmission |
| PP-012 |
SA00205 |
Fariborz Mansour- Ghanaei |
Prevalence of Hepatitis B and C in Hemodialysis Patients in Guilan, North Province of Iran |
| PP-013 |
SA00443 |
Chien-Hsieh Chiang |
Metabolic Factors and HBV DNA Levels |
| PP-014 |
SA00461 |
Heon Ju Lee |
Risk assessment for hepatocellular carcinoma development according to on-treatment virological responses during long-term lamivudine therapy in hepatitis B virus-related liver diseases |
| PP-015 |
SA00622 |
Burcak Evren Tasdogan |
THE FREQUENCY OF HEPATİTİS B INFECTION IN PATIENTS WİTH ULCERATIVE COLITIS, DO THEY HAVE AN INCREASED RISK FOR VIRAL HEPATITIS? |
| PP-016 |
SA00641 |
Makoto Arai |
Analysis of Long-term Follow-up in Patients with Hepatitis B e Antigen Negative Chronic Hepatitis B |
| PP-017 |
SA00668 |
Jing-jing NIE |
D1: Major Subgenotype of Hepatitis B Virus among Uigur Patients in Xinjiang Uygur Autonomous Region of China |
| PP-018 |
SA00698 |
Junying Qi |
Outcomes in 161 Patients with Decompensated Hepatitis B: A Single Center Study |
| PP-019 |
SA00717 |
Zhan Yang |
The relationship between disease progression in patients with chronic hepatitis B and gene copy number variation of PD-1 |
| PP-020 |
SA00748 |
Yagaanbuyant Dahgwahdorj |
Epidemiological changing of HBV infection in Mongolia |
| PP-021 |
SA00835 |
Wei Zhang |
A Cross-Sectional Study of Hepatitis B Vaccination Rate in High Risk Adult Population in Beijing |
| PP-022 |
SA00918 |
Jian Gong |
Impact of HBsAg carriage of mothers on effectiveness and persistence of Hepatitis B vaccine immunization |
| PP-023 |
SA01042 |
Tao Han |
To investigate the cause and clinical outcome of 289 HBV infection patients with acute-on-chronic liver failure (ACLF) |
| PP-024 |
SA01117 |
IOANNIS ELEFSINIOTIS |
Vaccination-induced protection rates against hepatitis B among pregnant women in Greece: far away from the ideal target. |
| PP-025 |
SA01195 |
Xiang-sheng Xu |
Exhaustion of HBsAg-Specific B-cell Response Correlates with Liver Pathogenesis during Chronic Hepatitis B Virus Infection in Humans |
| PP-026 |
SA01196 |
Zheng Zhang |
Cytokine-dependent up-regulation of natural killer cell cytotoxicity associate with liver damage and fibrosis in patients with chronic hepatitis B |
| PP-027 |
SA01237 |
Benjamin Cowie |
Outcomes of a complex dynamic mathematical model of hepatitis B virus in Australia |
| PP-028 |
SA01238 |
Benjamin Cowie |
Developing a mathematical model of hepatitis B in Australia – a new way of engaging an ancient, emergent pathogen |
| PP-029 |
SA01265 |
Moon Seok Choi |
A Multi-center, Nation-wide, Cross-sectional, Epidemiologic Study to Investigate Clinical and Laboratory Characteristics of HBeAg Positive and Negative Chronic Hepatitis B Patients in Korea |
| PP-030 |
SA01309 |
Chao shuang Lin |
Status of HBV infection and vaccination among health care workers in a public teaching hospital |
| PP-031 |
SA01313 |
Jun Wu |
Enhanced Surveillance of Acute Hepatitis B in Canada, 1998 to 2008 |
| PP-032 |
SA01327 |
Li Wanyu |
Association of IFN-λ gene in the Chinese han population with hepatitis B virus infection |
| PP-033 |
SA01401 |
Hong-Ying Chen |
The variation of serum level of interleukin-15 and it’s significances in patients with chronic hepatitis B virus infection |
| PP-034 |
SA01412 |
Xie Tiansheng |
Development and Validation of HBQOL-cn |
| PP-035 |
SA01454 |
Hairong Wei |
Inhibitory receptor NKG2A tempers NK cells against hepatitis B virus in active chronic hepatitis B |
| PP-036 |
SA01505 |
Hsiu-Lien Hung |
Incidence and Determinants for Hepatitis B e Antigen Seroclearance |
| PP-037 |
SA01526 |
Chuen-Fei Chen |
Long-term repeated measurements of hepatitis B viral load and the risk of HCC |
| PP-038 |
SA01527 |
Wei-Ju Su |
Reduction of the Incidence of Acute Hepatitis B after Universal Hepatitis B Immunization Program in Taiwan |
| PP-039 |
SA01560 |
Seong Woo Lim |
Virological and Clinical Features in Patients with HBsAg Seroclearance after Antiviral Treatment |
| PP-040 |
SA01572 |
Manash Sarma |
Hepatitis B Seroprevelance in Liver Disease Patients from India: Correlation between HBeAg Status, HBV Viral Load and Genotypes |
| PP-041 |
SA01581 |
Jing Liu |
The Epidemiological Features of Spontaneous Decrease of HBV DNA Level in CHB/LC Patients in South China |
| PP-042 |
SA01720 |
Hasan Ozkan |
Loss of HBsAg antigen in 894 HBsAg+ Patients During Long Term Follow Up |
| PP-043 |
SA01771 |
Anca Trifan |
Usefullness of transient elastography and Fibrotest to differentiate inactive hepatitis B carriers from HBe Ag-negative chronic hepatitis B |
| PP-044 |
SA00145 |
Xing Tongjing |
Effect of different markers on the study of T regulatory cells in patients with chronic hepatitis B infection |
| PP-045 |
SA01256 |
Ying-Tang Gao |
Measurement of Covalently Closed Circular DNA of Hepatitis B Virus by Real-time PCR and Its Preliminary Application |
| PP-046 |
SA01291 |
Ichiro Kumagai |
Differences among genotype, subgenotype, and mutation of precore and corepromoter regions of hepatitis B virus in patients with self-limiting acute hepatitis both in Japan and China |
| PP-047 |
SA01678 |
Lubiao Chen |
Relationship between SNP rs2660 on OAS-1 Gene and Spontaneous HBeAg Seroconversion in Chronic HBV Infection |
| PP-048 |
SA00083 |
HU Ai-rong |
Comparison of quantitative fluorescent polymerase chain reaction（QF-PCR） with the COBAS TaqMan test for hepatitis B virus(HBV) DNA in serum samples and clinical analysis of HBV-DNA in different clinical features |
| PP-049 |
SA00117 |
Shuhei Hige |
Hepatitis B core-related antigen in association with hepatocellular carcinoma. |
| PP-050 |
SA00198 |
Fariborz Mansour-Ghanaei |
Relationship between serum HBV DNA level and liver histology in HBV carriers with normal ALT in Guilan province,Iran |
| PP-051 |
SA00203 |
Farahnaz Jokar |
Occult Hepatitis B virus infection in hemodialysis patients of Rasht |
| PP-052 |
SA00223 |
Weiliang Tang |
Risk Factors of Prognosis for Patients with Severe Hepatitis B |
| PP-053 |
SA00228 |
Amarsanaa Jazag |
Current status and paradox in HBV diagnosis and management in Mongolia |
| PP-054 |
SA00350 |
Yongnian HAN |
Scoring systems based on laboratory tests for identifying acute hepatitis B among patients firstly presenting hepatitis B virus-related acute hepatitis |
| PP-055 |
SA00427 |
Ioannis Elefsiniotis |
Spontaneous preterm birth in women with HBeAg-negative chronic hepatitis B virus (HBV) infection. The value of maternal and cord blood data. |
| PP-056 |
SA00428 |
Ioannis Elefsiniotis |
Spontaneous preterm birth is associated with HBsAg-positive status among pregnant women in Greece. |
| PP-057 |
SA00539 |
Yeon Seok Seo |
A simple and accurate algorithm for avoiding unnecessary liver biopsy in patients with chronic hepatitis B |
| PP-058 |
SA00624 |
Maurizia R. Brunetto |
HBsAg serum levels help to identify inactive, genotype D, HBV carriers |
| PP-059 |
SA00839 |
Jun LI |
Dynamic Change of Specific CTLs in Patients with Acute Hepatitis B |
| PP-060 |
SA00914 |
Yuexin
Zhang |
Carboxyhemoglobin levels and its clinical significance in patients with viral hepatitis |
| PP-061 |
SA00946 |
Rui Zhang |
Hepatitis B virus transfusion risk in China: proficiency testing for the detection of hepatitis B surface antigen mutants |
| PP-062 |
SA00984 |
Shao-lin Zhao |
Quantitative detection of hepatitis B virus in peripheral blood mononuclear cells during the course of treatment patients with chronic hepatitis B |
| PP-063 |
SA00987 |
Jiawu Song |
The Development of Biosensor-based Microarray for HBV Genotyping and Preliminary Clinical Study |
| PP-064 |
SA01012 |
Li-Yuan Wang |
Aberrant statue of oxidative stress in chronic hepatitis B patients with elevated serum total bilirubin |
| PP-065 |
SA01075 |
SU zhi-jun |
Study on peripheral blood lymphocytes subsets in patients with chronic hepatitis B infection |
| PP-066 |
SA01124 |
Mamun Mahtab |
Study of fibroscn as a non-invasive marker of liver fibrosis in patients with chronic hepatitis B |
| PP-067 |
SA01142 |
Jia-ji Jiang |
An investigation on relevant factors of hepatic steatosis in patients with chronic hepatitis B |
| PP-068 |
SA01229 |
Tao Han |
Serum Thymosin β4 Levels in Liver Failure Patients Caused by Chronic Hepatitis B Virus Infection |
| PP-069 |
SA01366 |
Jing You |
The variation of peripheral T-lymphocyte subpopulations and serum interferon-γ and interleukin-4 levels in patients with chronic hepatitis B virus infection |
| PP-070 |
SA01456 |
Chao Zhao |
Identification of Autoantibodies in Sera of Hepatitis B Virus Transgenic Mice |
| PP-071 |
SA01489 |
Seiko Togo |
Clinical Significance of Measurement of HBs antigen in Chronic Hepatitis B Virus-Infected Patients with HBe antigen |
| PP-072 |
SA01512 |
Hwai-I Yang |
Development and Validation of a Predictive Risk Score for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B |
| PP-073 |
SA01530 |
Xieer Liang |
Liver Stiffness Measurement in Patients with Hepatitis B Flare Influenced Majorly by Bilirubin: Is There still a Role for Alanine Aminotransferase? |
| PP-074 |
SA01724 |
Xiangdong Ren |
Quantitative analysis of HBV mutants may help understand viral pathogenesis |
| PP-075 |
SA01746 |
Shuang Meng |
Nuclease-resistant double-stranded DNA controls or standards for hepatitis B virus nucleic acid amplification assays |
| PP-076 |
SA01765 |
Yuming Wang |
Mechanism of HBV-related Liver Failure |
| PP-077 |
SA00100 |
Dipendra Raj Pandeya |
Expression and Purification of a Functional Human HBV Polymerase |
| PP-078 |
SA00625 |
Chien-Hung Chen |
Risk Predictors of Reactivation of Hepatitis B Virus Following HBeAg Seroconversion in Chronic Hepatitis B Patients with or without Interferon-based Therapy |
| PP-079 |
SA00627 |
Ting-Chih Chen |
Evolution of HBV genomes in HBeAg-positive carriers: Comparison between genotype B versus C at different stages |
| PP-080 |
SA00773 |
Chang Soo Choi |
Associations Between the X Gene Mutations and Clinical Severity of Liver Disease in Patients With Chronic Hepatitis B Virus infection |
| PP-081 |
SA01133 |
Lin Yang |
NH2-terminal region of Hepatitis B virus X protein is required for functions of HBx :promoting growth and proliferation of hepatocellular carcinoma cell via induction of cell cycle progression |
| PP-082 |
SA01374 |
Seng Gee Lim |
Core Internal Deletions in Spontaneous, Interferon-induced or Lamivudine treated HBeAg Seroconverter patients |
| PP-083 |
SA01509 |
Antonio Bertoletti |
T cell receptor-like antibodies targeting HBV infected hepatocytes: a new tool for drug delivery and pathogenic studies. |
| PP-084 |
SA00040 |
Jie Li |
STAT1 demethylation is involved in the resistance of Hepatitis B Virus to Interferon alpha |
| PP-085 |
SA00061 |
Ye Zhang |
Overexpression of Toll-like receptor 2/4 modulates the activities of CD4+CD25+ regulatory T cells in chronic hepatitis B virus infection |
| PP-086 |
SA00067 |
Mamun Mahtab |
PROFILE OF HBeAg -VE CHRONIC HBV INFECTION IN BANGLADESH |
| PP-087 |
SA00127 |
Yasuteru Kondo |
Heat shock proteins derived from HBV-infected-hepatocyte enhance the function of regulatory T cells by TLR2 signaling |
| PP-088 |
SA00158 |
Wen-Chun Liu |
Correlation between mutation and methylation of CpG islands of hepatitis B virus and viral kinetics in natural course patients |
| PP-089 |
SA00227 |
Jie Li |
HBcAg induces Interleukin 10 inhibits HBcAg-specific Th17 responses in Chinese chronic hepatitis B patients |
| PP-090 |
SA00264 |
Hui Chen |
Expression and localization of APOBEC3G in PBMC and liver tissue in different chronic HBV infected patients |
| PP-091 |
SA00294 |
Zhang Zhenhua |
Establishment and mutation analysis of the reference sequences for HBV genotypes B and C that are prevalent in China |
| PP-092 |
SA00313 |
Dongping Xu |
Features and clinical implications of HBV genotypes and mutations in basal core promoter/precore region in 507 Chinese patients with acute and chronic hepatitis B |
| PP-093 |
SA00318 |
Dongping Xu |
Association of HBV mutations in basal core promoter and precore regions with severity of liver disease--an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure |
| PP-094 |
SA00335 |
Yue-Yong Zhu |
siRNA alters the proliferation of hepatocellular carcinoma cell line HepG2 via reducing the expression of COX-2 gene |
| PP-095 |
SA00337 |
Jia-ji Jiang |
Clinical significance of hepatocyte expression of HBV surface antigen |
| PP-096 |
SA00346 |
Ye Zhang |
Th17 cells correlate with acute but not chronic hepatitis B virus infection |
| PP-097 |
SA00406 |
Zhao Yongxiao |
Relationship between local cellular immune in liver and viral replication in different phases of chronic HBV infection |
| PP-098 |
SA00416 |
Xiao Gang Huang |
Vα24 NK T cells in peripheral blood and their correlations with the severity of hepatic injury in patient with chronic hepatitis B virus infection |
| PP-099 |
SA00434 |
Shuang Wu |
Hepatitis B e antigen suppresses innate immune response |
| PP-100 |
SA00464 |
Du Juan |
Evaluation of two HBV Promoters for Sustained Transgene Expression in Mouse Liver |
| PP-101 |
SA00471 |
ROLI SAXENA |
Association of IL-12 and Interferon - gamma genotypes in the progression and development of HBV-related hepatocellularcarcinoma in India |
| PP-102 |
SA00491 |
Jialun Yu |
The primary study on the relationship between the characteristic of the hepatitis B virus S gene quasispecies and the clinical outcomes of HBV infection |
| PP-103 |
SA00513 |
Naichaya Chamroonkul |
Utility of INNO-LiPA HBV DR v2 Testing in Chronic Hepatitis B Patients who Developed Viral Breakthrough During Oral Nucleos(t)ide Analogues Treatment |
| PP-104 |
SA00567 |
Shao Qiang Wu |
Comparative analysis of the TCR beta chain CDR3 spectratyping of infiltrating T lymphocytes in the liver and in peripheral blood in patients with chronic hepatitis B |
| PP-105 |
SA00573 |
Jingxian Yang |
Detection of antiviral resistance mutations in HBV C-genotype chronically infected Chinese patients with or without antiviral treatment |
| PP-106 |
SA00596 |
Lingli Yang |
Serum HBV RNA in patients with chronic hepatitis B virus infection |
| PP-107 |
SA00702 |
Sayabold Batmunkh |
Current distribution of HBV serological markers in chronic HBV patients and its significance in Mongolia |
| PP-108 |
SA00755 |
Xin Zhang |
Mutation in BCP and precore region of HBV genome was in connection with the progression of the chronic hepatitis B |
| PP-109 |
SA00759 |
Hong Tang |
Application of the HBV replication mouse model in the biological study of HBV |
| PP-110 |
SA00760 |
Hong Tang |
Hepatitis B virus X protein augments HBV transcription and replication in vivo |
| PP-111 |
SA00771 |
Cai QingXian |
Expression of Suppressor of Cytokine Signaling-1 Gene in PBMC of Hepatitis B Virus-related Liver Diseases and Its Clinical Significance |
| PP-112 |
SA00786 |
Mindie H. Nguyen |
Hepatitis B virus reverse transcriptase mutations (rt) were not detected in treatment-naïve patients with chronic hepatitis B (CHB) patients using sensitive INNO LiPA HBV DR3 in a prospective community-based study |
| PP-113 |
SA00818 |
Xue-ping Nan |
Circulating CD4+CD25high regulatory T cells and expression of PD-1 and BTLA on CD4+ T cells in patients with chronic hepatitis B virus infection |
| PP-114 |
SA00903 |
CHENGHUI HUANG |
Detection of hepatitis B virus DNA in blood donors with HBsAg negative but anti-HBc positive and analysis of S gene variation |
| PP-115 |
SA00907 |
Jian-qi Lian |
Th17 cells correlate with acute but not chronic hepatitis B virus infection |
| PP-116 |
SA00957 |
Wu Jing |
Characteristics and clinical significance of peripheral blood NK cells subsets in patients with chronic hepatitis B virus infection |
| PP-117 |
SA01050 |
Zhen-Ping Wu |
The resistance mutation pattern of hepatitis B virus during adefovir dipivoxil sequential therapy after lamivudine resistance |
| PP-118 |
SA01096 |
Pattaratida Sa-nguanmoo |
Virological factors of hepatitis B virus associated with vaccine failure in Thailand |
| PP-119 |
SA01113 |
Nauman Arif Jadoon |
Hepatitis B Vaccination Status of Health Care Workers at a Tertiary Care Hospital In Multan |
| PP-120 |
SA01122 |
Lei Lu |
Early Viral Kinetics of Hepatitis B Virus DNA in Chronic Hepatitis B Patients Treated with Lamivudine or Clevudine Therapy |
| PP-121 |
SA01127 |
Mamun Mahtab |
Profile of HBeAg -ve Chronic HBV Infection in Bangladesh |
| PP-122 |
SA01260 |
Zhen-Ping Wu |
The evolution of hepatitis B virus quasispecies during sequential therapy after lamivudine resistance |
| PP-123 |
SA01321 |
Ning Li |
Expression level of toll-like receptors and the prognosis of chronic severe hepatitis B |
| PP-124 |
SA01328 |
Li Wanyu |
The imbalance of B lymphocyte subsets in chronic HBV infection |
| PP-125 |
SA01362 |
Pu-jun Gao |
Beta 2-glycoprotein I binds to hepatitis B surface antigen |
| PP-126 |
SA01370 |
Seng Gee Lim |
Viral Quasispecies Evolution Pattern In Chronic Hepatitis B Patients Treated With Lamivudine |
| PP-127 |
SA01419 |
Zhiping Qian |
Expression of nuclear factor-κB and its regulated cytokines in dendritic cells in patients with chronic severe hepatitis B and its clinical significance |
| PP-128 |
SA01444 |
Bin Zhou |
A case with triplicate genotypes infection showed evidence for recombination of HBV |
| PP-129 |
SA01448 |
Dong Jiu Zhao |
Involvement of p38 signaling pathway in the process of antiviral activity of A3G toward Hepatitis B Virus |
| PP-130 |
SA01557 |
Vlad Ratziu |
Modelling the impact of treatment with entecavir on long-term mortality, morbidity and healthcare costs of chronic hepatitis B in France |
| PP-131 |
SA01608 |
Jerzy Jaroszewicz |
Hepatitis B Surface Antigen (HBsAg) Levels in the Natural History of Hepatitis B Virus (HBV)-Infection: A European Perspective |
| PP-132 |
SA01708 |
Don Ha LI |
Study on the Relationship Between The HBV cccDNA copies of Hepatocytes and Serum HBV DNA'HBsAg in Chronic Hepatitis B Patients |
| PP-133 |
SA01776 |
Laura Belloni |
STAT1/2 transcription factors in the control of cccDNA transcription and HBV replication |
| PP-134 |
SA00207 |
Yidan Qian |
48 weeks observation of Telbivudine in treatment of chronic severe hepatitis B |
| PP-135 |
SA00899 |
Lunli Zhang |
The significance of ISG15/USP18 expression in predicting response to interferon therapy for chronic hepatitis B |
| PP-136 |
SA00906 |
Xi Zhang |
Patients receiving entecavir with a partial virologic response at week 48 achieved HBV DNA undetectable at year 2 with no change of therapy |
| PP-137 |
SA00915 |
Myoung Hee Lee |
Efficacy of Entecavir in Patients with Hepatitis B Virus-related Decompensated Liver Cirrhosis |
| PP-138 |
SA00921 |
Şükran Köse |
Results of Entecavir Treatment in Chronic Hepatitis B (CHB) Patients |
| PP-139 |
SA01244 |
Jeong Han Kim |
Comparision of Clevudine and Entecavir as primary treatment for Chronic Hepatitis B |
| PP-140 |
SA01388 |
Yi-Hsiang Huang |
Analysis of short-term survival of lamivudine treatment in patients with decompensated cirrhosis related to hepatitis B |
| PP-141 |
SA01390 |
Byung Hoon Han |
Long-term adefovir mono therapy in patients with lamivudine-resistant chronic hepatitis B |
| PP-142 |
SA01480 |
Scott Bowden |
Quantification of hepatitis B surface antigen: evaluation of the Roche Elecsys® prototype HBsAg quantification assay. |
| PP-143 |
SA01619 |
Hyun Woong Lee |
Entecavir Rescue Therapy versus Adefovir Combination Therapy in Lamivudine-refractory Patients with Chronic Hepatitis B |
| PP-144 |
SA00038 |
Hao Wang |
Long term efficacy of nine-year Lamivudine treatment in chinese chronic hepatitis B patients with advanced liver fibrosis. |
| PP-145 |
SA00065 |
Mamun Mahtab |
SEQUENTIAL TREATMENT OF CHILDREN WITH CHB IN IMMUNOTOLERANT PHASE WITH LAMIVUDINE AND INTERFERON |
| PP-146 |
SA00066 |
Mamun Mahtab |
ANTIVIRAL POTENTIALITY OF A COMBINATION THERAPY (ANTIVIRAL AND IMMUNE THERAPY) IN INCIDENTALLY-DETECTED CHRONIC HEPATITIS B VIRUS-INFECTED SUBJECTS (IDHAS) IN BANGLADESH |
| PP-147 |
SA00086 |
Yida Yang |
De novo lamivudine and adefovir dipivoxil combination therapy for patients with decompensated cirrhosis resulting from chronic hepatitis B. |
| PP-148 |
SA00094 |
Li-jie Sun |
Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure |
| PP-149 |
SA00120 |
Truong BaTrung |
A STUDY OF PEG-IFN ALPHA-2A (PEGASYS) TREATMENT IN HBeAg-POSITIVE CHRONIC HEPATITIS B |
| PP-150 |
SA00170 |
Li-Jun Mi |
Use of Tenofovir DF (TDF) in Chinese-American Pregnant Patients with Chronic Hepatitis B (CHB)- Case Series Report |
| PP-151 |
SA00189 |
Md. Golam Azam |
Lamivudine for chronic hepatitis B virus infection: efficacy and drug resistance during long-term treatment |
| PP-152 |
SA00193 |
Su Sheng |
Combination treatment of chronic hepatitis B using interferon alpha and anti-HBV specific active immunotherapy |
| PP-153 |
SA00201 |
Yong-Ning Xin |
The Effects Of Acidic Mucopolysaccharide From Stichopus Japomicus Selenka On HBV Transgenic Mice |
| PP-154 |
SA00235 |
Mamun Mahtab |
Initial 1 Year Experience with Telbivudine in Bangladesi CHB Patients |
| PP-155 |
SA00245 |
Yue-qiu Gao |
Effect of Bushen Recipe on immune effector molecules of T lymphocytes |
| PP-156 |
SA00258 |
Jian guo Yu |
The analyse of effectiveness and safety in Chronic hepatitis B treated by adefovir dipivoxil combined with bicyclol |
| PP-157 |
SA00259 |
Jian guo Yu |
Study of liver biopsy in chronic HBV carriers |
| PP-158 |
SA00262 |
Yanqing Huang |
Therapeutic effects of N-acetylcysteine on the patients with chronic severe hepatitis B |
| PP-159 |
SA00274 |
Md. Golam Azam |
Peginterferon alfa-2b (12 KD) in chronic hepatitis B patients in Bangladesh: A preliminary study |
| PP-160 |
SA00277 |
Dongying Xie |
Telbivudine Induces Marked Inhibition of PD-1 Expression and Enhances IFN-γ and CD8+ T-cell Production in HBeAg-positive Patients With CHB Who Achieve Early HBeAg Seroconversion |
| PP-161 |
SA00331 |
Sheng Su |
Study on immune effects of anti-HBV specific active immunotherapy(SAI) in the treatment of Chinese chronic HBV infection. |
| PP-162 |
SA00332 |
Jia-ji Jiang |
The potential of dendritic cells-derived exosomes in immunotherapy of chronic hepatitis B infection |
| PP-163 |
SA00336 |
Jia-ji Jiang |
Predictors of Adefovir dipivoxil monotherapy to HBeAg positive patients |
| PP-164 |
SA00341 |
Yuexin Zhang |
CD4+CD25+ regulatory T cells decline in patients with chronic severe hepatitis B |
| PP-165 |
SA00390 |
Ed Gane |
TENOFOVIR PROVIDES EFFECTIVE RESCUE THERAPY FOR PATIENTS FOLLOWING TREATMENT FAILURE WITH ADEFOVIR THERAPY |
| PP-166 |
SA00439 |
S. Nimanong |
Telbivudine Add-on Therapy for a Cirrhotic Patient with Chronic Hepatitis B Who Failed Sequential Treatment with Lamivudine/Adefovir: A Case Report |
| PP-167 |
SA00475 |
Yang-fang Jiang |
Enhancing anti-hepatitis B virus mediated immune response by nucleos(t)ide analogs and Thymosin-alpha1 therapy |
| PP-168 |
SA00476 |
HUEI-RU CHENG |
Outcome of chronic hepatitis B patients receiving peginterferon alfa-2a therapy in Taiwan: A Single Center Experience |
| PP-169 |
SA00490 |
Qing Xie |
Long term efficacy of entecavir therapy on viral suppression in nucleoside-naïve chronic hepatitis B Patients |
| PP-170 |
SA00515 |
Soo Young Park |
Early Development of Clevudine Resistance in Chronic Hepatitis B Patients with Prior Lamivudine Therapy |
| PP-171 |
SA00529 |
Sae Hwan Lee |
LAMIVUDINE-ADEFOVIR COMBINATION THERAPY COULD NOT SUFFICIENTLY CLEAR THE INITIAL YMDD MUTANTS IN HBEAG-POSITIVE PATIENTS WITH LAMIVUDINE-RESISTANT CHRONIC HEPATITIS B |
| PP-172 |
SA00555 |
June
Sung Lee |
Initial Viral Response is the Most Important Predictor of the Emergence of Resistant Mutants after Adefovir Treatment in Lamivudine-Resistant Chronic Hepatitis B |
| PP-173 |
SA00556 |
Chun Kyon Lee |
Comparison of Entecavir and Clevudine for treatment of Chronic Hepatitis B |
| PP-174 |
SA00568 |
Hong You |
Two patterns of ALT flare to predict long-term viral response after nucleos(t)ide treatment in HBeAg-positive chronic hepatitis B patients: Virus-induced or Host-induced? |
| PP-175 |
SA00595 |
Golam Azam |
Telbivudine in chronic hepatitis B: One-year result among Bangladeshi patients |
| PP-176 |
SA00653 |
Jia-ji Jiang |
Efficacy of domestic Adefovir dipivoxil (AGD) monotherapy to chronic hepatitis B |
| PP-177 |
SA00654 |
YS Lee |
Treatment with Clevudine Results in Sustained Antiviral Response Associated with Continued HBsAg Decrease Additional 2-Year Post-Treatment in Chronic Hepatitis B Patients |
| PP-178 |
SA00655 |
Yimin Mao |
Efficacy and safety of one year therapy with adefovir dipivoxil (ADV) in a large sample of Chinese patients with chronic hepatitis B (CHB) |
| PP-179 |
SA00657 |
Li Jun |
Colligation Analysis And Evaluation On The Efficacy Of Combined Traditional Chinese Medicine And Western Medicine For Severe Hepatitis |
| PP-180 |
SA00661 |
Jia-ji Jiang |
Short-term therapy of entecavir versus laminvudine for hepatitis B virus associated acute hepatic failure |
| PP-181 |
SA00686 |
M C Ngu |
Severe Osteomalacia and Hypophosphataemic Renal Tubular Dysfunction in 2 Patients on Long Term Adefovir Dipivoxil for Chronic Hepatitis B |
| PP-182 |
SA00733 |
En-Qiang Chen |
Biochemical and virological response of adefovir dipivoxil and entercavir for the treatment of naïve chronic hepatitis B patients in China |
| PP-183 |
SA00780 |
Ena Lyn Ang |
Entecavir in Lamivudine-Refractory Chronic Hepatitis B Infection—A Meta-Analysis |
| PP-184 |
SA00787 |
Sang-Hoon Ahn |
Telbivudine combination with Adefovir vs Adefovir monotherapy in HBeAg positive Chronic Hepatitis B (CHB) patients with lamivudine resistance |
| PP-185 |
SA00799 |
Mindie Nguyen |
Complete virologic response (CVS) to entecavir (ETV) therapy in adefovir (ADV) experienced patients: A Multicenter Study. |
| PP-186 |
SA00804 |
Mindie H. Nguyen |
Long-term outcome in treatment-naïve HBeAg-negative chronic hepatitis B (CHB) patients treated with entecavir 0.5mg (ETV) or adefovir 10mg (ADV) in a real-life clinical setting |
| PP-187 |
SA00806 |
Karsten Wursthorn |
Quantitation of Serum HBeAg Levels During Prolonged Telbivudine Treatment and Correlation with Outcome |
| PP-188 |
SA00807 |
Karsten Wursthorn |
Serum HBsAg Kinetics in HBeAg-Positive (+) Patients During 3 Years Telbivudine Treatment in Chronic Hepatitis B (CHB) |
| PP-189 |
SA00810 |
Aldo Trylesinski |
Outcomes for newborns exposed to telbivudine during pregnancy. Retrospective analysis of the Novartis safety and clinical databases |
| PP-190 |
SA00814 |
Hong Ren |
Telbivudine induced HBeAg Seroconversion in Chronic Hepatitis B (CHB) patients is durable during 2 years off-treatment follow-up |
| PP-191 |
SA00817 |
In Hee Kim |
Virologic Response and Resistance of 48-Week Entecavir Therapy Versus Clevudine in Naïve Patients with Chronic Hepatitis B |
| PP-192 |
SA00826 |
Henry LY Chan |
Efficacy and safety of telbivudine vs lamivudine in the treatment of decompensated Chronic Hepatitis B (CHB) for 2 years |
| PP-193 |
SA00840 |
TATSUO KANDA |
Secondary Antiviral Treatment Failure against Hepatitis B Virus by Nucleos(t)ide Antivirals |
| PP-194 |
SA00850 |
Meiqin Zhu |
Efficacy And Safety Of Lamivudine For Preventing Mother-to-infant Transmission Of HBV-A Systematic Review. |
| PP-195 |
SA00861 |
Marie Ellaine Velasquez |
Lamivudine in Hepatitis B Reactivation in Patients with Rheumatologic Diseases on Chronic Immunosuppression |
| PP-196 |
SA00869 |
Il Han Song |
Clinical Efficacy of Adefovir Mono-switch versus Adefovir Add-on Therapy in Patients with Lamivudine-resistant Chronic Hepatitis B |
| PP-197 |
SA00887 |
Jeong Han Kim |
Comparision of Clevudine and Entecavir as primary treatment for Chronic Hepatitis B |
| PP-198 |
SA00888 |
Yan Chang Lei |
A recombinant HBV vector mediated liver specfic anti-HBV activity of C- terminal truncated pokeweed antiviral protein |
| PP-199 |
SA00896 |
Xinmin Wang |
The psychological status and life quality of patients with chronic hepatitis B |
| PP-200 |
SA00908 |
Yan Chang Lei |
Inhibition of Hepatitis B Virus Replication by HumanAPOBEC3 Editing Enzymes containing double cytosine deaminase domain |
| PP-201 |
SA00911 |
Da Mi Lee |
Add on lamivudine to adefovir monotherapy for the treatment of lamivudine-resistant chronic hepatitis B patients |
| PP-202 |
SA00917 |
Yuexin Zhang |
nucleosides analog can improve the prognosis of chronic severe hepatitis B patients in short-term |
| PP-203 |
SA00920 |
Xinjian Fan |
Research on anti-HBV activities of four flavonoids from Halenia elliptica D. Don |
| PP-204 |
SA00922 |
Rintaro Mikata |
De novo hepatitis B virus (HBV)-related hepatitis after allogeneic hematopoietic stem cell transplantation |
| PP-205 |
SA00926 |
LI Hua Sun |
Clinical study of adeforvir dipivoxil treatment for HBeAg-positive patients with chronic hepatitis B for 4 years |
| PP-206 |
SA00929 |
Xiao Tang Fan |
Subsequent therapy for chronic hepatitis B patients following Lamivudine initial no response |
| PP-207 |
SA00936 |
Padaki Nagaraja Rao |
Efficacy of Entecavir in Chronic Hepatitis B Liver Disease Patients- A Prospective Observational Study |
| PP-208 |
SA00939 |
P Marcellin |
Large International, Observational Study of Patients With Chronic Hepatitis B Infection Treated With Peginterferon Alfa-2a [40KD] (PEGASYS): the S-collate Cohort |
| PP-209 |
SA00949 |
P Marcellin |
On-Treatment Decline in Serum HBsAg Levels Predicts Sustained Immune Control 1 Year Post-Treatment and Subsequent HBsAg Clearance in HBeAg-Negative Hepatitis B Virus-Infected Patients Treated With Peginterferon Alfa-2a [40KD] (PEGASYS) |
| PP-210 |
SA00960 |
T Piratvisuth |
Sustained Immune Control 1 Year Post-Treatment With Peginterferon Alfa-2a [40KD] (PEGASYS) is Durable up to 5 Years Post-Treatment and is Associated With a High Rate of HBsAg Clearance in HBeAg-Negative Chronic Hepatitis B |
| PP-211 |
SA00970 |
T Piratvisuth |
On-treatment decline in serum HBsAg levels predicts sustained immune control and HBsAg clearance 6 months post-treatment in HBeAg-positive hepatitis B virus-infected patients treated with peginterferon alfa-2a [40KD] (PEGASYS) |
| PP-212 |
SA00991 |
Lin Qing |
E.A.C.H.:Entecavir(ETV) versus Adefovir(ADV) for Patients with Chronic Hepatitis B :Therapy for 48 weeks |
| PP-213 |
SA00993 |
Hui Wang |
Virologic Efficacy Of Peginterferon α-2a Therapy In Chronic Hepatitis B Patients With Persistently Normal ALT Levels |
| PP-214 |
SA01047 |
Yida Yang |
Dynamic analysis of CD127 expression on the memory CD8 T cells from chronic hepatitis B patients treated with peginterferon α-2a |
| PP-215 |
SA01101 |
Minning Song |
Adefovir treatment of chronic hepatitis B 3-year observation of clinical efficacy and drug resistance |
| PP-216 |
SA01116 |
Ming-Juan Yuan |
Lamivudine efficacy on the prevention and treatment of hepatitis B virus reactivation induced by glucocorticoid in the patients with HBV infection |
| PP-217 |
SA01125 |
Mamun Mahtab |
Sequential Treatment of Children with CHB in Immunotolerant Phase with Lamivudine and Interferon |
| PP-218 |
SA01129 |
Mamun Mahtab |
Antiviral Potentiality of a Combination Therapy (Antiviral and Immune Therapy) in Incidentally-Detected Chronic Hepatitis B Virus-Infected Subjects (IDHAS) in Bangladesh |
| PP-219 |
SA01143 |
Minghua Qi |
Changing of HBVDNA and HBeAg in HbeAg(+) patients with Ldt Treatment |
| PP-220 |
SA01165 |
Cai QingXian |
A meta-analysis of the treatment of severe chronic hepatitis B with lamivudine |
| PP-221 |
SA01180 |
Li-Chun Wang |
Lamivudine plus adefovir dipivoxil versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patients |
| PP-222 |
SA01184 |
Weixia Liu |
Establishment of Cell Lines Secreting preS2-TLM-ScFv Fusion Protein Targeted Translocating into HBsAg Expressed Cells |
| PP-223 |
SA01189 |
Pauli Virtanen |
Electron transfer in therapeutic alkaloids triggers anastomoses in traumatized liver blood flow. |
| PP-224 |
SA01192 |
Jie Yusheng |
A 96-weeks study of antiviral therapy for patients with HBeAg-negative cirrhosis |
| PP-225 |
SA01227 |
Liang Peng |
Efficiency of recombinant yeast hepatitis B vaccination in neonates from South of China |
| PP-226 |
SA01232 |
Nancy Leung |
Changing experience of antiviral therapy for chronic hepatitis B patients in Hong Kong |
| PP-227 |
SA01241 |
Andrea Marengo |
8 YEARS OF LAMIVUDINE (LAM) THERAPY IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) IN A SINGLE CENTER: LONG-TERM RESPONDERS IN A RETROSPECTIVE ANALYSIS |
| PP-228 |
SA01263 |
Bian Zhong-Qi |
siRNA Targeting HBV Gene Inhibits Hepatitis B Virus Expression and Replication in BHK-21 Cells |
| PP-229 |
SA01294 |
Shiwu Ma |
The Dynamics of CD8 Lymphocyte TCR Spectratypes Perturbation Associated with Virological Response in CHB Patients Treated with Nucleot(s)ide Analogues |
| PP-230 |
SA01302 |
Fang-Qin Li |
Preliminary clinical study of anti-HBV-DC combine Thymosin-a1 treating the HBeAg negative chronic hepatitis B patients |
| PP-231 |
SA01325 |
Wen-Bao Zhu |
Preliminary clinical study of anti-HBV-DC combine Thymosin-a1 treating the inactive HBsAg carrier |
| PP-232 |
SA01341 |
Seng Gee Lim |
Low Risk Of Multiresistant HBV In A Followup Study Of Lamivudine With Adefovir Switch Strategy |
| PP-233 |
SA01348 |
Seng Gee Lim |
Outcomes Of Treatment For Chronic Hepatitis B Cirrhosis On Lamivudine-Adefovir Therapy |
| PP-234 |
SA01349 |
Jin Qinglong |
Effect of Lamivudine and Telbivudine on creatine kinase in hepatitis B antiviral treatment |
| PP-235 |
SA01363 |
Yan-fang Jiang |
Interleukin-33 Inhibits Hepatitis B Virus Replication in the Livers of Transgenic Mice |
| PP-236 |
SA01377 |
Jun-qi Niu |
The increased expression of 2B4(CD244) on natural killer cells in chronic hepatitis B patients treated with Telbivudine |
| PP-237 |
SA01408 |
Jiang-Ying Yang |
Preliminary clinical study of anti-HBV-DC combine lamivudine and Thymosin-a1 treating the chronic hepatitis B virus carriers |
| PP-238 |
SA01425 |
Stephan Kaiser |
Telbivudine Add-on Therapy in an HBeAg-Negative Cirrhotic Patient With a Suboptimal Response to Tenofovir |
| PP-239 |
SA01441 |
Sheikh Mohammad Fazle Akbar |
A therapeutic nasal vaccine containing both HBsAg and HBcAg was safe, had antiviral potential and induced antigen-specific immunity in patients with chronic hepatitis B |
| PP-240 |
SA01445 |
Sheikh Mohammad Fazle Akbar |
Mechanism of restoration of immune responses of chronic hepatitis B patients during lamivudine therapy: increased antigen processing and presentation by dendritic cells |
| PP-241 |
SA01458 |
Byung Chul Yoo |
A Comparison of 12 months and 24 months Treatment Efficacy between Clevudine and Entecavir Therapy for Chronic Hepatitis B |
| PP-242 |
SA01468 |
Yongyan Chen |
Adjuvant effects of IL-12 on HBV vaccination in mouse models |
| PP-243 |
SA01474 |
Pochamana Phisalprapa |
HBeAg index as an early predictor of response in chronic hepatitis B, HBeAg positive patients treated with pegylated interferon |
| PP-244 |
SA01497 |
Megan Crane |
Decline in HBV-specific CD4+ T cells following initiation of nucleoside reverse transcriptase (NRTI) therapy for chronic hepatitis B virus (HBV) infection |
| PP-245 |
SA01498 |
Min Seub Kwac |
Efficacy of 48 weeks entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir |
| PP-246 |
SA01524 |
Nikhil Patel |
Tenofovir rescue therapy for patients with viral resistance to Lamivudine and/or Adefovir treatment |
| PP-247 |
SA01541 |
Jong Eun Yeon |
Three year treatment of Adefovir (ADV) mono- vs. ADV & lamivudine (LMV) combination in HBeAg positive LMV resistant chronic hepatitis B patients |
| PP-248 |
SA01561 |
Nikhil Patel |
Comparing efficacy and safety of Lamuviduine + Tenofovir and Telbivudine + Tenofovir regimen for primary treatment failure in HBV infection |
| PP-249 |
SA01576 |
Yao Xie |
HBsAg Clearance And Seroconversion After Treatment With PEGASYS In Chronic Hepatitis B Virus-infected Patients With Low Serum HBsAg Level And Undetectable HBV DNA |
| PP-250 |
SA01582 |
Ronglong Jiang |
Efficacy and Safety of Peginterferon Alfa-2a in HBeAg-positive Chronic Hepatitis B Patients with ALT Levels >10 Times Upper Limit of Normal |
| PP-251 |
SA01590 |
S.S. Zhu |
Evaluation of Safety and Efficacy of Extended Pegainterferon-α-2a Therapy in Children with HBeAg-positive Chronic Hepatitis B |
| PP-252 |
SA01592 |
S.S. Zhu |
Evaluation of the Effect of Extended Peginterferon-α-2a Therapy on Physical and Psychological Development in Children with HBeAg-positive Chronic Hepatitis B |
| PP-253 |
SA01600 |
Mustafa Yakut |
LONG-TERM RESULTS OF LAMIVUDINE TREATMENT IN PATIENTS WITH ANTI HBe POSITIVE CHRONIC HEPATITIS B. |
| PP-254 |
SA01624 |
Han Jak Ryu |
Rescue efficacy of lamivudine and adefovir compared to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B |
| PP-255 |
SA01641 |
Joon Suk Kim |
HBsAg Titer Were More Efficiently Reduced by Clevudine in Patients with Cirrhosis than Those without Cirrhosis. |
| PP-256 |
SA01656 |
Han Jak Ryu |
Comparision of entecavir (ETV) monotherapy and lamivudine (LAM) plus adefovir (ADV) in patients with chronic hepatitis B who have sequentially failed with LAM and ADV |
| PP-257 |
SA01671 |
Hyun Young Woo |
A prospective randomized comparison of 96 weeks treatment efficacy between entecavir and adefovir in treatment naïve patients with chronic hepatitis B |
| PP-258 |
SA01702 |
Peng Hu |
LONG-TERM KINETICS OF HEPATITIS B VIRUS DNA LOAD DURING ADEFOVIR DIPIVOXIL TREATMENT IN NAÏVE PATIENTS |
| PP-259 |
SA01732 |
Young Eun Chon |
Partial virological response to entecavir in treatment-naive chronic hepatitis B: an evaluation of EASL guideline |
| PP-260 |
SA01733 |
Eugen Dumitru |
HBV related complications in HIV positive patients during HAART therapy |
| PP-261 |
SA01755 |
Chen Wen |
Nucleotide analogues can satisfactory inhibit HBV replication of HBeAg-negative chronic hepatitis B patients with ALT＜2×ULN |
| PP-262 |
SA01766 |
Ke Fan |
The study about the reasons of bad dependence of HBV patients |
| PP-263 |
SA01772 |
Laura Belloni |
Intrahepatic HBV status after 10 year of sustained viral suppresion by LAM: analysis of cccDNA sequence and expression. |
| PP-264 |
SA01790 |
Jiangbin Wang |
Antiviral efficacy and hepatic function improvement after 96 weeks entecavir treatment in nucleos(t)ide naive Chinese cirrhotic patients with chronic hepatitis B infection |
| PP-265 |
SA01813 |
J. Sollano |
Pretreatment Characteristics of Patients With Chronic Hepatitis B in the Philippines |
| PP-266 |
SA01823 |
Nancy Leung |
Efficacy and Safety of entecavir (ETV) versus adefovir (ADV) in chronic hepatitis B (CHB) patients with evidence of hepatic decompensation |
| PP-267 |
SA01824 |
Young-Oh Kwon |
Antiviral effects and safety of entecavir (ETV) versus lamivudine (LVD) in HBeAg-negative Korean chronic hepatitis B (CHB) patients: week 48 interim analysis |
| Presentation No. |
Submission No. |
Presenting Author |
Title |
| PP-268 |
SA00303 |
Yasir Waheed |
Risk factors and knowledge associated HBV/HCV transmission among the barbers community of Pakistan |
| PP-269 |
SA00333 |
Jia-ji Jiang |
A community based molecule epidemiology of hepatitis C virus in Fujian province of China |
| PP-270 |
SA00665 |
Weidong Zhang |
Impact of HIV-1 infection on the prognosis in HCV-HIV-1 co-infected Former Blood Donors |
| PP-271 |
SA00700 |
Raimonds Simanis |
Chronic
Hepatitis C Patient’s
Perception on Routes of Transmission of Hepatitis C Virus |
| PP-272 |
SA00730 |
Tsatsralt-Od
Bira |
High
Prevalence of Dual or Triple Infection of Hepatitis B, C, and Delta
Viruses Among Patients With
Chronic Liver Disease in Mongolia |
| PP-273 |
SA01178 |
Rino
Gani |
Sexual
Behavior Determine Heterosexual Transmission of Hepatitis C Virus in HCV-HIV
Co-infection Patient. |
| PP-274 |
SA01324 |
Lijun
Liu |
Distribution
of hepatitis C virus genotypes in patients with chronic hepatitis C infection
in China |
| PP-275 |
SA01521 |
Nikhil Patel |
CHANGING
SPECTRUM OF HEPATITIS C VIRUS INFECTION IN WESTERN INDIA |
| PP-276 |
SA01522 |
Jung
Woo Shin |
The
Impacts of Occult HBV Infection in Serum or Liver Tissue on Treatment
Response of Chronic Hepatitis C in Korea |
| PP-277 |
SA01668 |
Kenneth
Yan |
Retrospective
Analysis of Pan Asian Outcome of Response to Therapy for Hepatitis C - A
Multicenter Study (REPORT-C study) |
| PP-278 |
SA01507 |
Shuang
Meng |
A novel
real-time multiplex reverse transcriptase-polymerase chain reaction for the
detection of HCV RNA using the armored RNA as internal control |
| PP-279 |
SA00204 |
Farahnaz
Jokar |
Distribution
of HCV Genotypes in Hemodialysis Patients in Guilan, North Province of Iran |
| PP-280 |
SA00367 |
Aly Soliman |
DISCOVERY
OF THE MISSED LINK BETWEEN SCHISTOSOMIASIS AND HCV INFECTION |
| PP-281 |
SA00373 |
Hoda
Abd el moety |
FIBROSURE,APRI AND
FORNS SCORE VERSUS LIVER BIOPSY IN CHRONIC HCV INFECTION IN EGYPT. |
| PP-282 |
SA00423 |
Katsuharu
Hirano |
Evaluation
of the liver stiffness using transient elastography during peg-interferon
alpha -2b and ribavirin combination therapy in patients with chronic
hepatitis C. |
| PP-283 |
SA00536 |
Muhammad
Umar |
Histological
Outcome of Liver Biopsies in Patients With Chronic Hepatitis C- A Local
Experience |
| PP-284 |
SA00765 |
Sayabold
Batmunkh |
Introduction
of HCV quantification as a diagnostic tool in Mongolia: it’s significance and lessons learned. |
| PP-285 |
SA00828 |
Shahzad
Nasr Esfahani |
Development
of a new method for diagnosis of Hepatitis C virus infection by reverse
transcription-loop-mediated isothermal amplification |
| PP-286 |
SA01208 |
Naglaa
Allam |
Study of Iron, Copper and Alpha-1
Antitrypsin In Egyptian Patients With Chronic Hepatitis C |
| PP-287 |
SA01808 |
Ke Fan |
The
research about the condition of chronic hepatitis C patients with liver
cirrhosis |
| PP-288 |
SA00104 |
Narina
Sargsyants |
Predominant
genotype of hepatitis C virus in Armenia |
| PP-289 |
SA00166 |
Kuo-Chih
Tseng |
Effect
of Human Leukocyte Antigen Class I and II alleles on Hepatitis C viral load
among Chronic Hepatitis C Patients in Southern Taiwan |
| PP-290 |
SA00399 |
Qiang
Liu |
Hepatitis
C virus genotype-3a NS5A protein activates sterol regulatory element-binding
protein-1 and fatty acid synthase |
| PP-291 |
SA00484 |
Shingo
Nakamoto |
THE
EFFECTS OF HEPATITIS C VIRUS GENOTYPE 1B CORE AMINO ACID SUBSTITUTIONS AT
POSITIONS 70 AND 91 ON INTERFERON AND CYTOKINE-RELATED SIGNALING PATHWAY IN
HUMAN HEPATOMA CELLS |
| PP-292 |
SA00508 |
Cai
Rentian |
Dynamic
expression of PD-1 in T cell and clinic significance in
chronic hepatitis C patients |
| PP-293 |
SA00607 |
Ri Sho |
Expression
Profiling of TLR Signaling Pathway Genes in Human Hepatocytes Infected with
Cell Culture-Produced Hepatitis C Virus |
| PP-294 |
SA00681 |
Qiang
Ma |
A
vaccinia replication system for producing recombinant hepatitis C virus |
| PP-295 |
SA01666 |
Nyamdavaa
Tuul MD, PhD |
Prevalence
of porphyria cutanea tarda in hepatitis C virus infection in Mongolia |
| PP-296 |
SA01697 |
Chung-Feng
Huang |
The
characteristics of serum visfatin level in patients with chronic hepatitis C
virus infection-implications of virology and glucose abnormalities |
| PP-297 |
SA00018 |
Liudmila
Palgova |
DEBUT
OF SYSTEM SCLERODERMITIS SECONDARY TO HEPATITIS C ANTIVIRAL THERAPY |
| PP-298 |
SA00019 |
Liudmila
Palgova |
Results
of combined antiviral therapy HCV Infection of by peginterferon alpha- 2a and
ribavirin in the Republic of Kazakhstan. |
| PP-299 |
SA00124 |
Shaban
R. Abdulsalam Bagar |
PREVALENCE
OF HEPATITIS C VIRUS AMONG PATIENTS ATTENDING IBN-SINA HOSPITAL IN SIRT,
LIBYA |
| PP-300 |
SA00173 |
Run-Xuan
Shao |
Hepatitis
C Virus Replication Induce NF Kappa B System Activation |
| PP-301 |
SA00175 |
Run–Xuan Shao |
SOCS3
Suppresses HCV Replication in an mTOR-dependent Manner |
| PP-302 |
SA00554 |
Mohamed
Hadzri Hasmoni |
Hepatitis
C Genotyping in Haemodialysis Patients and the Development of Genotyping
Method Based on TaqMan Probe Real-Time PCR |
| PP-303 |
SA00565 |
Chang
Kuo-Chin |
Prediction
of viremia of hepatitis C virus (HCV) infection using a third generation
anti-HCV enzyme immunoassay test in hemodialysis patients |
| PP-304 |
SA00938 |
Rathindra
mohan Mukherjee |
Spectrum
of Incidentally Detected Hepatitis C Virus Infection in Southern India- A Prospective Study |
| PP-305 |
SA01074 |
Nauman
Arif Jadoon |
Impact
of Hepatitis C Virus Infection On Glycemic Control and Lipid Profiles Of
Diabetic Patients |
| PP-306 |
SA01097 |
Srunthron Akkarathamrongsin |
Prevalence
and Genotypes of Hepatitis C Virus in Migrant Workers from Cambodia, Laos and
Myanmar in Thailand |
| PP-307 |
SA01179 |
Rino Gani |
Attenuation
of Necroinflammation and Fibrosis in HCV – HIV Co-infection Patients with Severe
Immunodeficient |
| PP-308 |
SA01251 |
Om
Parkash |
What
matters in a liver biopsy core specimen in chronic hepatitis C : the size or number of portal tract! A cross sectional
study at tertiary care hospital. |
| PP-309 |
SA01358 |
Lixin
Zhang |
Hepatitis
C virus genotypes in Shandong province: The prevalence and clinical
significance |
| PP-310 |
SA01699 |
Subhash
Medhi |
Expression
Of Toll-Like Receptor-3 (TLR3) And Mitochondrial Antiviral Signaling Protein
(MAVS) In Naive And Anti-Viral Therapy Receiving Patients With Chronic
Hepatitis C Virus Infection |
| PP-311 |
SA00153 |
Malgorzata
Pawlowska |
Pegylated
interferon alpha-2a and ribavirin in the treatment of children with Chronic
Hepatitis C. |
| PP-312 |
SA00312 |
Koichi
Takaguchi |
An
Innovation of the Hepatitis C Therapy for the Patients Refractory to
Pegylated Interferon alfa-2b / Ribavirin Combination Therapy : Combination
use of Interferon-beta with Double Filtration Plasmapheresis |
| PP-313 |
SA00418 |
Yeong
Jin Song |
Tailored
therapy for treatment-naive chronic hepatitis C with pegylated Interferon
alfa and Ribavirin: real practice experience |
| PP-314 |
SA00429 |
Byung
Jin Choi |
24weeks
treatment with pegylated interferon alfa plus ribavirin may be possible in
genotype 1 chronic hepatitis C patients with rapid virological response who
have low pretreatment viremia. |
| PP-315 |
SA00465 |
Qiuxia
Fu |
Bioluminescence
imaging of Hepatitis C virus NS3/4A serine protease activity in cells and
living animals |
| PP-316 |
SA00870 |
Daisuke
Maruoka |
Prognosis
of Chronic Hepatitis C After Interferon Therapy by Long-Term Cohort Study |
| PP-317 |
SA00894 |
SeokHyun
Kim |
Relapse
rate after pegylated interferon alpha 2a and ribavirin therapy in patients
with chronic hepatitis C |
| PP-318 |
SA01161 |
Li Duan |
Prediction
of Chinese hepatitis C virus CTL epitopes and analysis on immunogenicity of
multi-epitopes antigen gene |
| PP-319 |
Offline
3 |
Claudio
Pasquinelli |
Safety,
Tolerability, Pharmacokinetics and Antiviral Activity following Single and
Multiple-dose Administration of BMS-650032, a novel HCV NS3 Inhibitor, in
subjects with Chronic Genotype 1 HCV Infection |
| PP-320 |
Offline
4 |
Andrew
J Muir |
A Phase
1b Dose-Ranging Study of 4 Weeks of PEG-Interferon (IFN) Lambda (PEG-IFN-λ) in Combination with Ribavirin (RBV) in
Patients with Chronic Genotype 1 Hepatitis C Virus (HCV) Infection |
| PP-321 |
Offline
5 |
R.E.Nettles |
BMS-790052
is a First-in Class Potent Hepatitis C Virus (HCV) NS5A Inhibitor for
Patients with Chronic HCV Infection: Results from a Proof-of-concept Study |
| PP-322 |
SA00096 |
Jian-Wu
Yu |
Analysis
of the efficacy of treatment with peginterferon alpha-2a and ribavirin in
patients coinfected with hepatitis B virus and hepatitis C virus. |
| PP-323 |
SA00102 |
Chun-Hsiang
Wang |
A
Prospective Study Using Artificial Neural Network Model Based On Single
Nucleotide Polymorphisms And Other Clinical Factors To Predict Therapeutic
Response Of Combined Pegylated Interferon And Ribavirin In Patients With
Chronic Hepatitis C |
| PP-324 |
SA00105 |
Narina
Sargsyants |
Comparison
of liver function tests in responders and non-responders of the treatment
with PEG Interferon Alfa 2a plus ribavirin in chronic hepatitis C |
| PP-325 |
SA00106 |
Mohan
Kumar |
Long
term sustain viral response in chronic hepatitis c relapser patients with peg
inerferone who relapse after conventional interferone thearpy in northern
area of pakistan |
| PP-326 |
SA00142 |
Vasileios
Papadopoulos |
Should
active injecting drug users receive treatment for chronic hepatitis C? |
| PP-327 |
SA00152 |
Gulnara
Aghayeva |
Diabetes
mellitus and Insulin resistance in hepatitis C patients. |
| PP-328 |
SA00232 |
Mamun
Mahtab |
Estimation
of Insulin Resistance in Patients with Hepatitis B and Hepatitis C Virus
Related Chronic Liver Disease |
| PP-329 |
SA00324 |
Eduardo
Vilar Gomez |
Antioxidant
and immunomodulator effect of Viusid ® in patients with chronic hepatitis C:
a double-blind, placebo-controlled study. |
| PP-330 |
SA00340 |
Ronglin
Zheng |
Interferon-2a
decreases expression of TBC1D20, a possible cofactor involved in the
replication of HCV in hepatocytes |
| PP-331 |
SA00409 |
Manal
El-Hamamsy |
The
impact of serum autoantibodies among chronic hepatitis C genotype 4(HCV) patients attending a national center of HCV
treatment program in Egypt |
| PP-332 |
SA00437 |
Gamal
Shiha |
Efficacy
of new PEG-Interferon α- 2a
(Reiferon Retard®) plus Ribavirin in Egyption Patients with Chronic Hepatitis
C |
| PP-333 |
SA00477 |
Muzzaffar
Gill |
OUTCOMES
OF CONSEUS INTERFERON AND RIBA THERAPY FOR CHRONIC HEP C G3 PATIENTS WHO
RELAPSED WITH PREVIOUS PEG-INTERFERON AND RIBA THERAPY |
| PP-334 |
SA00493 |
Rika
Ishii |
Occurrence
of hepatocellular carcinoma after achieving sustained virological response to
interferon therapy for chronic hepatitis C |
| PP-335 |
SA00503 |
Patrick
Marcellin |
Peginterferon
alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) has a wide safety margin
in patients infected with HCV genotype 1 |
| PP-336 |
SA00504 |
Maribel
Rodriguez-Torres |
Peginterferon
alfa-2a (40KD) (PEGASYS®) plus ribavirin (RBV) for chronic hepatitis C (CHC)
in HIV-HCV co-infected patients: final results of the PARADIGM study |
| PP-337 |
SA00533 |
Muhammad
Umar |
Effectiveness
of 24 weeks combination therapy for treatment of Hepatitis- C |
| PP-338 |
SA00577 |
Gill
Muzzaffar |
RAPID
VIROLOGICAL RESPONSE IS A PREDICTOR OF SUSTAINED VIROLOGICAL RESPONSE IN CHRONIC HEP C G3
PATIENTS TREATED WITH PEGASYS AND RIBAVIRIN |
| PP-339 |
SA00579 |
Muzzaffar
Gill |
OUTCOMES
OF CHRONIC HEPC G3 CIRRHOTICS TREATED WITH PEGINTRON AND RIBAVIRIN |
| PP-340 |
SA00594 |
Doha
Taie |
Hepatocyte
Growth Factor Activator In Liver Biopsies of Egyptian Patients with Hepatitis
C Virus-Related Chronic Hepatitis: Correlation With Hepatic Repair |
| PP-341 |
SA00599 |
Tadashi
Goto |
Prospective
Randomized Controlled “Head to
Head” Trial of Peginterferon
alpha-2a Versus Peginterferon alpha-2b in Combination With Ribavirin
(IHIT-II) Study. The Second Report. |
| PP-342 |
SA00679 |
Masayuki
Kurosaki |
Impact
of Mutations in ISDR and Core Region of HCV on Pretreatment Prediction of
Sustained Virological Response to Pegylated-interferon Plus Ribavirin Therapy
Revealed by Classification and Regression Tree Analysis |
| PP-343 |
SA00688 |
I Shyan
Sheen |
SPLENECTOMY
WITH SUBSEQUENT ANTIVIRAL TREATMENT IS BENEFICIAL FOR HEPATITIS C,
COMPENSATED CIRRHOTICS WITH THROMBOCYTOPENIA |
| PP-344 |
SA00715 |
Dong
Hyun Sinn |
Efficacy
of the Currently Recommended Ribavirin Dose in Koreans: Need for Reassessment
of Ribavirin Dosing Regimen |
| PP-345 |
SA00725 |
Naglaa
Allam |
Interferon-induced
thyroid dysfunction in chronic hepatitis C in the Middle East |
| PP-346 |
SA00726 |
SH Park |
Efficacy
and tolerability of peginterferon alfa plus ribavirin in the routine daily
treatment of chronic hepatitis C patients in Korea; a multi-center,
retrospective observational study |
| PP-347 |
SA00754 |
S
Pianko |
Final
results of ACHIEVE-1: albinterferon alfa-2b plus ribavirin in treatment-naïve
patients with genotype 1 chronic hepatitis C |
| PP-348 |
SA00762 |
W-L
Chuang |
Final
results of ACHIEVE-2/3: albinterferon alfa-2b plus ribavirin in
treatment-naïve patients with genotype 2/3 chronic hepatitis C |
| PP-349 |
SA00778 |
Akio
Miyasaka |
Efficacy
of short term treatment with interferon-beta in patients with hepatitis C
virus serotype 2 and low viral load |
| PP-350 |
SA00805 |
Eugen
Georgescu |
FLUVASTATIN
IMPROVES EARLY (EVR) AND SUSTAINED (SVR) VIROLOGICAL RESPONSE IN CHRONIC
HEPATITIS C TREATED WITH PEGINTERFERON AND RIBAVIRIN. A PRELIMINARY STUDY. |
| PP-351 |
SA00819 |
YONGHONG
ZHANG |
The
contribution of HCV specific immunity to the control of disease progression
in chronic HCV infection in China |
| PP-352 |
SA00885 |
Zaigham
Abbas |
A
randomized trial of Interferon Alpha, ribavirin plus interferon gamma or
amantadine for HCV Genotype 3 non-responders and relapsers |
| PP-353 |
SA00951 |
Qing
Xie |
Changes
in microRNA expression profiles in HCV replicon-containing cell lines by IFN-β and ribavirin combination therapy. |
| PP-354 |
SA01002 |
Peter
Ferenci |
Baseline
characteristics and interim on-treatment responses from the real-world
PROPHESYS cohorts inform future treatment paradigms for chronic hepatitis C
(CHC) |
| PP-355 |
SA01003 |
Darrell
H. Crawford |
Predicting
SVR by combining early measurements of viral load with baseline
characteristics including fibrosis score: Enhanced potential to individualize
HCV treatment decisions |
| PP-356 |
SA01004 |
Samuel
S. Lee |
Predictors
of discontinuation and dose reduction in patients with chronic hepatitis C
treated with peginterferon alfa-2a (40KD) plus ribavirin in a multinational
open-label expanded access program |
| PP-357 |
SA01094 |
Gamal
Shiha |
Efficacy
of new PEG-Interferon α- 2a
(Reiferon Retard®) plus Ribavirin in Egyption Patients with Chronic Hepatitis
C |
| PP-358 |
SA01119 |
Kenneth
KL Yan |
Factors
Affecting Treatment Uptake of Patients with Chronic Hepatitis C in a Tertiary
Referral Hospital |
| PP-359 |
SA01164 |
Phil
McEwan |
A Need
for a Dynamic Approach to Modelling Disease Progression in Cost-Effectiveness
Studies of Antiviral Therapies in Patients with Chronic Hepatitis C. |
| PP-360 |
SA01166 |
Xuezhong
Lei |
Treatment
of Chinese patients with chronic hepatitis C with peginterferon alfa-2a
(40KD) plus ribavirin (RBV) |
| PP-361 |
SA01211 |
Alyaa
Sabry |
Evaluation of Egyptian patients with
chronic hepatitis C Genotype 4 with persistently normal ALT including
response to antiviral therapy |
| PP-362 |
SA01230 |
CJ Liu |
Peginterferon
alfa plus Ribavirin for 24 or 48 weeks in Genotype 1 Chronic Hepatitis C
Patients in Taiwan |
| PP-363 |
SA01297 |
Dominique
Larrey |
Nurse-provided
therapeutic education in patients with chronic hepatitis C treated by
Peg-Interferon-alpha2a-Ribavirin : impact on quality of life |
| PP-364 |
SA01301 |
Yoshiaki
Iwasaki |
A
Response-Guided-Therapy is Feasible in Peginterferon plus Ribavirin
Combination Therapy for Chronic Hepatitis C Patients with Genotype 1 and
Amino Acid Substitutions in the Core Region |
| PP-365 |
SA01315 |
Yi
Zhang |
Transfer
of Hepatitis C virus (HCV)-reactive T cell specificity for the treatment of
HCV-associated hepatocellular carcinoma |
| PP-366 |
SA01416 |
Masroor
Qazi |
EFFECT
OF DIABETES MELLITUS (DM) ON THE EFFICACY OF STANDARD INTERFERON (SdIF) PLUS
RIBAVIRIN COMBINATION THERAPY IN PATIENTS OF CHRONIC HEPATITIS C VIRUS (HCV)
GENOTYPE-3 |
| PP-367 |
SA01430 |
Chia-Yen
Dai |
Pegylated
interferon/ribavirin therapy for chronic hepatitis C patients who did not
response to previous conventional interferon/ribavirin therapy |
| PP-368 |
SA01558 |
Khin
May Oo |
Preliminary
findings on the effectiveness of heat-treated Enterococcus faecalis FK-23 preparation
in the management of hepatitis C carriers |
| PP-369 |
SA01591 |
Soo
Young Park |
Clinical
outcome of pegylated interferon plus ribavirin combination therapy for
chronic hepatitis C virus infection in Korea |
| PP-370 |
SA01602 |
Mustafa
Yakut |
Long
Term Follow-Up For The Patients Treated With Pegylated İnterferon Plus Ribavirin For Chronic Hepatitis
C |
| PP-371 |
SA01659 |
Nai-Jen
Hou |
Stem
cell transplantation for leukemia patients from chronic hepatitis C donors
with and without peginterferon-alfa and ribavirin pretreatment |
| PP-372 |
SA01663 |
Makoto
Kuboki |
Prevalence
and therapeutic significance of neutralizing anti-interferon antibodies to
interferon alpha among chronic hepatitis C patients non-responder to
peginterferon alpha 2a. |
| PP-373 |
SA01670 |
Necati
Ormeci |
A
prospective study to evaluate the prognostic value of Fibrotest, a non-invasive fibrosis markers, for predicting liver
fibrosis and the efficacy of peginterferon treatment on fibrosis formation in
patients with chronic HBV infection. |
| PP-374 |
SA01680 |
P.
Patrick Basu |
Effect
of High-Dose Ribavirin (RBV), Alinia (Nitazoxanide) and Pegylated Interferon
(PegIFN) alfa-2a in attaining Sustained Virologic Response (SVR) in Treatment
of Chronic Hepatitis C (ERAIS-C Trial) in Naïve Genotype 1 Patients |
| PP-375 |
SA01682 |
Shih-Jer
Hsu |
EARLY
VIRAL KINETICS PREDICTS VIROLOGIC RESPONSES TO PEGINTERFERON PLUS RIBAVIRIN
TREATMENT IN TAIWANESE PATIENTS WITH CHRONIC HEPATITIS C |
| PP-376 |
SA01688 |
Xiaoyuan
Xu |
Abnormal
glycometabolism in Chronic Hepatitis C: Insulin resistance impairs rapid virologic
response |
| PP-377 |
SA01712 |
Cristina
Cijevschi Prelipcean |
How can
we influence the sustained viral response in patients with chronic hepatitis
C and diabetes mellitus? |
| PP-378 |
SA01764 |
Saleem
Bokhari |
Scientific
Validation of an Efficient Herbal Formulation Against Hepatitis C |
| PP-379 |
SA01804 |
Masaru
Ogasawara |
Effectiveness
of Double Filtration Plasmapheresis for Hepatitis C Virus Genotype 1b
Patients with High Viral Load. |
| PP-380 |
SA01826 |
Ahmet
Uyanikoglu |
DURABILITY
OF SUSTAINED VIRAL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C |
| PP-381 |
SA01838 |
Claudio
Pasquinelli |
Safety,
Tolerability, Pharmacokinetics and Antiviral Activity following Single and
Multiple-dose Administration of BMS-650032, a novel HCV NS3 Inhibitor, in
subjects with Chronic Genotype 1 HCV Infection |
| PP-382 |
SA01839 |
AJ Muir |
A Phase
1b Dose-Ranging Study of 4 weeks of Peg-Interferon (IFN) Lambda (Peg-IFN-λ) in combination with Ribavirin (RBV) in
Patients with Chronic Genotype 1 Hepatitis C Virus (HCV) Infection |
| Presentation No. |
Submission No. |
Presenting Author |
Title |
| PP-501 |
SA00132 |
Naoki
Uyama |
Fascin,
an actin bundling protein, may regulate functions of hepaticstellate cells
through FAK-PI3K-Akt pathway |
| PP-502 |
SA00151 |
Yoichi
Yasuda |
(–)-Epigallocatechin gallate prevents carbon
tetrachloride-induced rat hepatic fibrosis by inhibiting the expression of
the PDGFRβ and IGF-1R |
| PP-503 |
SA00213 |
Canjie
Guo |
Signaling
pathways involved in hepatic stellate cell activation are regulated by miRNAs |
| PP-504 |
SA00486 |
Hu
Guo-xin |
Effects
of hydroxycamptothecin on the proliferation and apoptosis of rat hepatic
stellate cells in vitro |
| PP-505 |
SA00684 |
Jia-ji
Jiang |
The
effects of TGF-β1 on the mesenchymal stem
cells transplantation on hepatic fibrogenesis and hepatoma in rats |
| PP-506 |
SA00709 |
R.P.
Gao |
Connective
tissue growth factor expression and its role in HBV-induced liver fibrosis |
| PP-507 |
SA00091 |
Olav A
Gressner |
Connective
Tissue Growth Factor is an interleukin-6/ STAT3-regulated hepatic negative
acute phase protein |
| PP-508 |
SA00154 |
Sun
Jung Myung |
Exisulind
attenuates hepatic stellate cell activation and survival through JNK and
nuclear factor kappa B-dependent mechanism |
| PP-509 |
SA00185 |
Xin
Tong |
Changes
of hepatic proteome in DMN-induced cirrhosis/fibrosis and the effects of
Huangqi Tang intervention in rats |
| PP-510 |
SA00304 |
Xu Li |
Upregulation
Of Angiotensin Converting Enzyme 2 In Hepatic Fibrosis By |
| PP-511 |
SA00306 |
Hongdong
Xie |
Proteomic
Analysis of the Effect of FuZhengHuaYu Recipe on Fibrotic Liver in Rats |
| PP-512 |
SA00520 |
Li Wenting |
Pokeweed
antiviral protein (PAP) attenuates liver fibrosis through inhibiting Wnt/β-catenin pathway. |
| PP-513 |
SA00578 |
Zhan
Zhang |
A study
on Salidroside inhibits migration of hepatic stellate cell line |
| PP-514 |
SA00637 |
Yingdi
Liu |
Leptin
potentiates acetaldehyde-induced activation of hepatic stellate cells in
vitro |
| PP-515 |
SA00659 |
Yanfeng Bai |
Suppression
of tissue inhibitor of metalloproteinase-1 (TIMP-1) by recombinant
lenti-virus carrying small interfering RNA in hepatic stellate cells |
| PP-516 |
SA00796 |
Yu-Ping Wang |
Effects
of Blueberry on Hepatic Fibrosis and Phase ⅡEnzymes in Rats |
| PP-517 |
SA00800 |
Yu-ping
Wang |
Expression
of HO-1 in Rat hepatic fibrosis and the effect of Blueberry on its expression
pattern |
| PP-518 |
SA00854 |
Dingzhu
Shen |
Effect mechanism of CK8, CK18 and TCTP
in a rat model of hepatic fibrosis induced by CCl4 |
| PP-519 |
SA00856 |
Ming-Kuei
Tsai |
Effects
of salvianolic acids in platelet-derived growth factor-induced cell signaling
via p70 S6 kinase in rat hepatic stellate cells |
| PP-520 |
SA00867 |
Ting-Fang
Lee |
In
vitro and in vivo studies of kaerophyllin against hepatic fibrosis in rats |
| PP-521 |
SA00882 |
Bingfeng
Qiu |
Transdifferentiation
of hepatocytes mediated by TGF-β1 autocrined in hepatocytes after bile duck ligation rats |
| PP-522 |
SA00890 |
Ching-Fen Wu |
Hepatitis
C virus core protein induces oxidative stress and hepatic fibrogenesis |
| PP-523 |
SA00910 |
Hangping
Yao |
Enhanced
effect of soluble transforming growth factor-β receptor II and IFN-γ fusion protein in reversing hepatic fibrosis |
| PP-524 |
SA00916 |
Bibigul
Ilyassova |
The
signal molecules of autoimmunity in the pathogensis of liver cirrhosis caused
by chronic hepatitis B |
| PP-525 |
SA00962 |
Zhen
Zeng |
Effect
of Xiaozhang Cataplasm on ascites and gastrointestinal motility |
| PP-526 |
SA01100 |
SANG-WON
HONG |
Fucoidan
Prevents DMN-Induced Liver Fibrosis In Rats |
| PP-527 |
SA01115 |
Xu Li |
Angiotensin
II induces hepatocyte epithelial-mesenchymal-transition in vitro |
| PP-528 |
SA01155 |
Wu
Qi-kai |
Effects
of ZhengganHuayu Decoction on the Pathological Changes of Hepatic Fibrosis in
Rats |
| PP-529 |
SA01158 |
Tran
Bao Nghi |
REPRODUCIBILITY
OF TRANSIENT ELASTOGRAPHY BY FIBROSCAN ACCORDING TO THE DEGREE OF LIVE
FIBROSIS IN CHRONIC LIVER
DISEASES |
| PP-530 |
SA01298 |
Xin
Zeng |
Identification
of Anti-fibrogenic Components from Herbal Componds 861 In vitro and In vivo |
| PP-531 |
SA01317 |
Min
Cong |
Antifibrotic
Effects of Recombinant Adeno-Associated Viruses Carrying siRNAs Targeting
Tissue Inhibitor of Metalloproteinase-1 on CCL4 Induced Liver Fibrosis in
Rats |
| PP-532 |
SA01394 |
Tingbo
Liang |
RAPAMYCIN
INHIBITS LIVER FIBROSIS BY BLOCKING THE EPITHELIAL TO MENSENCHYMAL TRANSITION
OF HEPATOCYTES |
| PP-533 |
SA01427 |
Wisuit Pradidarcheep |
Activated
Hepatic Stellate Cells in Thioacetamide –Induced Cirrhosis Express M3 Muscarinic Receptor |
| PP-534 |
SA01471 |
Jin
Zixue |
NKT
cells exacerbate liver fibrosis in hepatitis B virus transgenic mice |
| PP-535 |
SA01479 |
Chunqiu
Hao |
Knockdown
of CTGF by RNAi inhibits growth and activation of hepatic stellate cells and
fibrosis of CCl4-cirrhotic liver |
| PP-536 |
SA01506 |
Jung Il
Lee |
The
Protective Effect of Resveratrol on Dimethylnitrosamine-induced Liver
Fibrosis in Rats |
| PP-537 |
SA01535 |
Xuemei
Li |
Effect
of herbal ingredients formula（CGA）on the metabolism of collagen in DMN induced
rat fibrotic liver |
| PP-538 |
SA01548 |
Subhadip
Ghatak |
An
insight into the anti-fibrotic efficacy of an Indian herb “Picrorhiza kurrooa”. |
| PP-539 |
SA01650 |
Chenghai
Liu |
N-acetylcysteine
effect on CoCl2 intoxicated
hepatic stellate cell line |
| PP-540 |
SA01694 |
Andrea
Noetel |
Neuronal
microRNAs targeting pluripotency factors like Lin-28 in myofibroblastic
differentiation |
| PP-541 |
SA00441 |
Gamal
Shiha |
Assessment
of Hepatic Fibrosis by FibroScan Compared with Liver Biopsy in Chronic
Hepatitis C Genotype 4 |
| PP-542 |
SA00538 |
Yeon
Seok Seo |
The
results of Fibroscan is affected by the respiration |
| PP-543 |
SA01095 |
Gamal
Shiha |
Assessment
of Hepatic Fibrosis by FibroScan Compared with Liver Biopsy in Chronic
Hepatitis C Genotype 4 |
| PP-544 |
SA01371 |
Beom
Kyung Kim |
A liver
stiffness measurement-based prediction model for liver cirrhosis, adjusting
serum aminotransferase levels in hepatitis B patients |
| PP-545 |
SA01447 |
Chun
Yeon Joo |
Non-invasive
assessment of hepatic fibrosis by measuring the liver stiffness and
biochemical markers in chronic liver disease |
| PP-546 |
SA01546 |
Ki Tae
Yoon |
Liver
stiffness measurement using acoustic radiation force impulse (ARFI) in
chronic liver disease |
| PP-547 |
SA00044 |
Zou
Meiyin |
The
clinical significance of serum Vascular Endothelial Growth Factor (VEGF) and
Model for End-stage Liver Disease (MELD) in patients with decompensated liver
cirrhosis |
| PP-548 |
SA00090 |
Olav A
Gressner |
Quality
control accepted intraanalytical and interlaboratory variations lead to
clinically relevant differences in calculated Fibrotest/ Actitest scores for
the serum-based classification of liver fibrosis |
| PP-549 |
SA00128 |
Seung
Ha Park |
The
Usefulness of Multiple Biomarkers for the Prediction of Significant Fibrosis
in Chronic Hepatitis B: A Critical Appraisal |
| PP-550 |
SA00417 |
Jun Long |
Serum
levels of adiponectin in patients with chronic hepatitis B virus infection
are decreased and associated with hepatic fibrosis progression |
| PP-551 |
SA00643 |
Jian
Zhang |
Applications
of Transient elastography (FibroScan) for the assessment of liver fibrosis |
| PP-552 |
SA00677 |
Haijun
Huang |
Metabolomic
analysis of the feces reveals malabsorption in liver cirrhosis patients
caused by Hepatitis B virus |
| PP-553 |
SA00767 |
R.T.
Gao |
Serum
Levels of TIMP-1 and TIMP-2 as Noninvasive Markers of Hepatic Fibrosis in
Patients with Chronic Hepatitis B. |
| PP-554 |
SA00772 |
Chun-Lei Fan |
Comparison
of Transient Elastography (FibroScan) with FibroTest and APRI for the
Prediction of Hepatitis B-Related Fibrosis |
| PP-555 |
SA00858 |
Raymond
Kwok |
Diabetes
Mellitus is associated with high liver stiffness measurements by Fibroscan® |
| PP-556 |
SA00862 |
Raymond
Kwok |
A pilot
study of Fibroscan®, Caffeine Breath test, APRI and AAR: comparison of non-invasive markers of
liver fibrosis in Chronic Hepatitis B patients. |
| PP-557 |
SA00979 |
Jun Ji |
Study
on the association between GP73 and liver fibrosis |
| PP-558 |
SA01044 |
Feng
Hui |
A
preliminary clinical study on two kinds of ultrasonic elastographic technique
for diagnosis of hepatic fibrosis |
| PP-559 |
SA01359 |
Pu-jun
Gao |
The
clinical significance of anti-beta2-GPI antibodies in the post-hepatitis B
liver diseases |
| PP-560 |
SA01570 |
Kausik
Das |
Liver
Stiffness Measure (LSM) in healthy subjects (HS) and in fatty liver or
chronic hepatitis (CH). |
| PP-561 |
SA01711 |
Catalina
Mihai |
Usefulness
of real time elastography for the evaluation of liver fibrosis in chronic B
and C viral hepatitis |
| PP-562 |
SA01825 |
Yusuf
Yilmaz |
Noninvasive
assessment of liver fibrosis with the aspartate transaminase to platelet
ratio index (APRI): usefulness in patients with chronic liver disease |
| Presentation No. |
Submission No. |
Presenting Author |
Title |
| PP-563 |
SA00141 |
Konstantinos
Mimidis |
Eplerenone
reverses spironolactone-induced painful gynaecomastia in patients with
cirrhosis: a clinical study |
| PP-564 |
SA00293 |
Hong
Joo Kim |
Endoscopic
Treatment of Fundal Gastric Varices by Sclerotherapy with
N-butyl-2-Cyanoacrylate |
| PP-565 |
SA00371 |
Hoda
Abd el moety |
STUDY
OF PORTAL AND SYSTEMIC LEVELS OF NITRIC OXIDE, ENDOTHELIN-1 AND PROCOLLAGEN
III PEPTIDE IN CHRONIC LIVER DISEASE IN EGYPT |
| PP-566 |
SA00414 |
Byung
Seok Kim |
Impact
of antibiotic prophylaxis on reduction of serum nitric oxide and prevention
of early rebleeding after endoscopic therapy in esophageal variceal hemorrhage:
a prospective randomized controlled trial |
| PP-567 |
SA00460 |
Heon Ju
Lee |
Does
proton pump inhibitor increase the risk of spontaneous bacterial peritonitis
in cirrhotic patients with ascites? |
| PP-568 |
SA00589 |
Moon
Young Kim |
The
Effect of Angiotensin Receptor Blocker, Candesartan and Nonselective beta
blocker, Propranolol Combination Therapy in Reduction of Portal Hypertension
compared to Propranolol Montherapy |
| PP-569 |
SA00697 |
AKIKO
MIYAMOTO |
BLOOD
OXYGENATION IN RATS WITH COMMON BILE DUCT LIGATION BREATHING 100% OXYGEN |
| PP-570 |
SA01577 |
Guan
Wee Wong |
Epidemiological
and Clinico-biochemical Comparison between Hepatitis B and Alcoholic Liver
Cirrhosis |
| PP-571 |
SA01658 |
Sang
gyune Kim |
THE
PARAMETERS OF DOPPLER ULTRASONOGRAPHY TO PREDICT GASTRIC VARICES IN PATIENTS
WITH CIRRHOSIS |
| PP-572 |
SA00070 |
Zheng
Sheng |
Analysis
of the risk factors of portal vein thrombosis in liver cirrhosis patients |
| PP-573 |
SA00325 |
Dae Won
Jun |
The
Correlation of Small Intestinal Bacterial Overgrowth, Orocecal Transit Time
and Gastrointestinal Symptoms in Patients with Liver Cirrhosis |
| PP-574 |
SA00329 |
Luis
Calzadilla |
Application
of a biochemical and clinical model to predict individual survival in
patients with end-stage liver disease |
| PP-575 |
SA00359 |
Pises
Pisespongsa |
Serum-ascites
albumin concentration gradient (SAAG) greater than 20 g/L can be used as
non-invasive indication for starting primary prophylaxis of esophageal
variceal hemorrhage (EVH) |
| PP-576 |
SA00404 |
Fei LIU |
Prognostic
evaluation of decompensated liver cirrhotic patients by means of MELD score
combined with PA |
| PP-577 |
SA00435 |
Xiao
Dinghong |
Effect
of Fuzheng Huayu Capsule on Preventing Upper Gastrointestinal Bleeding in
Cirrhotic Patients with Portal Hypertension: a Long-time Following-up |
| PP-578 |
SA00456 |
Lei Li |
The
Analysis of the DNA fingerpring of intestinal flora in liver cirrhotic
patients |
| PP-579 |
SA00516 |
Faouzi
SALIBA |
MELD,
MELD-Na, Child-Pugh and ICU Scores in Predicting Outcome of Cirrhotic
Patients Admitted for an Acute Severe Decompensation: results of a recent
cohort of 377 patients |
| PP-580 |
SA00534 |
Hamama-tul-
Bushra |
Endoscopic
Variceal Band Ligation in Chronic Liver Disease patients: experience at Holy
Family Hospital, Rawalpnidi. |
| PP-581 |
SA00540 |
Muhammad
Umar |
Liver
Disease Related Mortality, A Review of 10 Year Audit |
| PP-582 |
SA00542 |
Muhammad
Umar |
Upper
GI Endoscopic Findings in Patients with Chronic Liver Disease |
| PP-583 |
SA00548 |
Tien
Huey Lim |
Oral
L-Ornithine-L-Aspartate is safe and effective in patients with intractable
hepatic encephalopathy- the NZ Liver Transplant Unit experience |
| PP-584 |
SA00553 |
June
Sung Lee |
Incidenc
and Risk Factor of Renal Failure Induced by Bacterial Infection other than
Spontaneous Bacterial Peritonitis in Patients with Cirrhosis |
| PP-585 |
SA00629 |
Masroor
Qazi |
PROGNOSTIC
FACTORS OF MORTALITY IN PATIENTS WITH LIVER CIRRHOSIS (A TERTIARY CARE
HOSPITAL EXPERIENCE) |
| PP-586 |
SA00683 |
Satoko Uegaki |
Cystatin
C-based assessment of renal function is more reliable compared to
creatine-based assessment in cirrhotic patients |
| PP-587 |
SA00719 |
Sudhir
Gupta |
Evaluation
of Portal Hypertension in Children |
| PP-588 |
SA00722 |
Adrian
Goldis |
FibroScan
as a predictive tool for esophageal varices and variceal bleeding |
| PP-589 |
SA00768 |
Yun Zhai |
Immunology
foundation and clinical features of liver cirrhosis with bacterial infection |
| PP-590 |
SA00783 |
Naveen
Kalra |
CORRELATION
OF HVPG WITH CTP SCORE, MELD SCORE, SIZE OF VARICES, ASCITES AND ETIOLOGY IN
CIRRHOTIC PATIENTS |
| PP-591 |
SA00876 |
Seul Ki
Min |
The
Comparative Results of Endoscopic Variceal Obliteration, Endoscopic Band
Ligation, Balloon Occluded Retrograde Obliteration
for Secondary Prophylaxis of Gastric Variceal Bleeding. |
| PP-592 |
SA00877 |
Hong XU
|
The
application of “U”retroflexion ligation therapy on esophagogastric
varices(EGV1) |
| PP-593 |
SA00975 |
Feng
Xing |
Effect
of navel application with Chinese herbal cataplasm on patients with ascites
due to liver cirrhosis |
| PP-594 |
SA00995 |
Tongyu
Tang |
Prediction
of esophageal varices in patients with cirrhosis |
| PP-595 |
SA01006 |
Kun-He
ZHANG |
Risk
factor survey and prediction model establishment for onset of esophageal
varices bleeding |
| PP-596 |
SA01035 |
James
Li |
Epidemiology
of Patients with Liver Cirrhosis in a Single Tertiary Centre in Singapore |
| PP-597 |
SA01114 |
Moon
Young Kim |
Hepatogenous
Diabetes Mellitus in Liver Cirrhosis: Relationship with Portal Pressure and
Variceal Hemorrhage |
| PP-598 |
SA01123 |
Makoto
Segawa |
The
value of liver stiffness using FibroScan might be a predictive factor of the
portal vein pressure. |
| PP-599 |
SA01128 |
Shuangsuo
Dang |
Effects
of marrow hemopoiesis factor TPO, CM-CSF on circumference blood corpuscle， in liver cirrhosis patients |
| PP-600 |
SA01131 |
Shuangsuo
Dang |
Expression
of CD34+ cell in bone marrow of cirrhosis patients |
| PP-601 |
SA01132 |
Shahid
Ahmed |
Factors
predicting the recurrence of spontaneous bacterial peritonitis in patients
with cirrhosis |
| PP-602 |
SA01154 |
Zhengjie Xu |
The
influence of glucose metabolism disorders on complications of cirrhosis |
| PP-603 |
SA01159 |
Hoang
Trong Thang |
The
platelet count, the spleen diameter and the platelet count/spleen diameter
ratio as a predictor of esophageal varices in cirrhosis |
| PP-604 |
SA01400 |
Karla
Maria Nomorosa |
EFFECT
OF ANGIOTENSIN RECEPTOR BLOCKERS IN REDUCING PORTAL PRESSURE IN CIRRHOTIC
PATIENTS WITH PORTAL HYPERTENSION: THE ENRICH STUDY |
| PP-605 |
SA01481 |
Paulus Kusnanto |
Non-Endoscopic
Prediction of Esophageal Varices Grade in Patients with Bleeding Liver Cirrhosis |
| PP-606 |
SA01568 |
Femmy
Nurul Akbar |
Correlation
between Degree of Cirrhosis by Child-Pugh Criteria and Liver Stiffness in Liver Cirrhosis
Patients |
| PP-607 |
SA01584 |
Ju Hee
Seo |
Predictors
of the development of refractory ascites in patients with hepatitis B
virus-related cirrhosis experiencing the first episode of ascitic
decompensation |
| PP-608 |
SA01611 |
ASHRAF
ELFAKHRY |
Endoscopic
Band Ligation Compared To Cyanoacrylate Injection For Management Of Gastric
Varices: A Randomized Controlled Study |
| PP-609 |
SA01626 |
Zheng-jie
Xu |
The
influence of glucose metabolism disorders on complications of liver cirrhosis |
| PP-610 |
SA01705 |
Eric Wee |
Endoscopic
Assisted Insertion of the Sengstaken-Blakemore Tube in Uncontrollable Acute
Esophageal Variceal Bleeding: A New and Novel Beside-The-Scope Method Under
Direct Endoscopic Visualization. |
| PP-611 |
SA01717 |
Hosny
Salama |
Efficacy of autologous haematopoietic stem cells transplantation in treating Egyptian
patients with end-stage chronic liver diseases . |
| PP-612 |
SA01726 |
Adriano
M Pellicelli |
Portal
vein thrombosis in cirrhotic patients: safety and efficacy of low dosage of
enoxaparin. |
| PP-613 |
SA01794 |
Tjahjadi
Robert Tedjasaputra |
Hepatic
Vein Flow Velocity Measurement Using Ultrasound Vascular Doppler as A
Parameter of Severity of Liver Cirrhosis and Grading of Esophageal Variceal |
| PP-614 |
SA00058 |
Ehab
Abdel-Khalek |
Circadian
pattern of acute variceal bleeding in Egyptian patients |
| PP-615 |
SA00351 |
Junqi
Niu |
Immunologic
Characterization of Post-hepatitis Cirrhosis Caused by HBV and HCV Infection |
| PP-616 |
SA00430 |
Eiji
Kakazu |
Branched-chain
amino acids improve the maturation of dendritic cells in patients with
advanced cirrhosis ex vivo. |
| PP-617 |
SA00453 |
Yun
Zhai |
Octreotide
decreases portal pressure: The Hepatic stellate cells may play a pivotal role |
| PP-618 |
SA00455 |
Lei Li |
The
cardiac hemodynamics change in liver cirrhotic patients |
| PP-619 |
SA00766 |
Li-jun Wang |
The
production of hydrogen sulfide and its significance in hepatic stellate cells |
| PP-620 |
SA00790 |
Kun-He
Zhang |
Interleukin-1A
but not Interleukin-1B gene polymorphisms is associated with HBV-related
hepatic cirrhosis |
| PP-621 |
SA00924 |
Dong-Hai YAN |
The association of polymorphisms of transforming growth factor-β1 with the susceptibility of HBV-related hepatic cirrhosis |
| PP-622 |
SA00932 |
Kun-He ZHNAG |
The gender difference in susceptibility of HBV-related cirrhosis is associated with polymorphisms of several genes |
| PP-623 |
SA00967 |
Kun-He ZHANG |
Gene polymorphisms of liver enzymes for toxin metabolism not associated with susceptibility of HBV-related hepatic cirrhosis |
| PP-624 |
SA01685 |
Ketut Mariadi |
Upper Gastrointestinal Bleeding was Associated With Higher IL-6 Level in Liver Cirrhosis |
| Presentation No. |
Submission No. |
Presenting Author |
Title |
| PP-668 |
SA01598 |
Fangfang Bu |
ASPP2 is a negative regulator of epithelial–mesenchymal transition and metastasis in HCC |
| PP-669 |
SA01617 |
Motohisa Tada |
Down-regulation of Suppressor of fused (Sufu) is implicated in the pathogenesis of human hepatocellular carcinoma. |
| PP-670 |
SA01623 |
Jian Zhao |
Epigenetic silence of ASPP1 and ASPP2 genes promotes tumor growth in HBV-positive hepatocellular carcinoma |
| PP-671 |
SA00050 |
Mengsen Li |
Alpha-fetoprotein inhibited the activity of PTEN caused retinoid-resistance of human hepatoma Cells |
| PP-672 |
SA00113 |
Zhizhen Dong |
Dynamic Expression of HIF-1α during the Development of Hepatocellular Carcinoma and Its Clinical Values |
| PP-673 |
SA00224 |
Mei-Li Chen |
Glutathione S-Transferase P1 (GSTP1) Gene Polymorphism Increases Age-Related Susceptibility to Hepatocellular Carcinoma |
| PP-674 |
SA00283 |
Judy Wai Ping Yam |
Caveolin-1 is overexpressed and promotes human hepatocellular carcinoma tumorigenesis via activation of HGF signaling |
| PP-675 |
SA00319 |
Yu-Yuan Li |
The roles of osteopontin in the invasiveness of hepatocellular carcinoma |
| PP-676 |
SA00436 |
Sen-Yung Hsieh |
Aberrant activation of ERBB3 in human hepatocellular carcinoma |
| PP-677 |
SA00611 |
Guangming Li |
Histone deacetylases (HDACs) and hepatocellular carcinoma (HCC) |
| PP-678 |
SA00631 |
Fanyin Meng |
MicroRNA-125b and hepatocellular carcinoma: the epigenetic association study and functional analysis |
| PP-679 |
SA00640 |
Xing Gu |
Four Polymorphisms Influence the HBV-Related HCC Susceptibility and Progression in Chinese Population |
| PP-680 |
SA00669 |
Heng-Hui ZHANG |
Foxp3 promoter demethylation controls Foxp3 gene expression in human hepatoma cell lines |
| PP-681 |
SA00670 |
Heng-Hui ZHANG |
The expression of Foxp3 in hepatocellular carcinoma cells inhibit anti-tumor immune response and contribute to the tumor cells migration and invasion |
| PP-682 |
SA00699 |
Ryosuke Muroyama |
Not HBx but fusion HBx translated from HBV integrant is implicated in the development and progression of hepatocellular carcinoma |
| PP-683 |
SA00720 |
Liang Teng |
Identification and Characterization of a Novel MicroRNA Involved In the Development of liver Cancer |
| PP-684 |
SA00781 |
Dae-Ghon Kim |
Altered BAMBI/TGF-beta-signaling by Hepatitis B Virus X protein in Hepatocellular Carcinoma |
| PP-685 |
SA00824 |
Angela M. Liu |
microRNA-375 targeting YAP signaling pathways in hepatocellular carcinoma |
| PP-686 |
SA00831 |
Jie Chen |
Association of CXCL10 G-201A polymorphism and the risk of HCC among Chinese cirrhotic CHB patients |
| PP-687 |
SA00874 |
Dean Tian |
The pro-apoptosis effect of p75NTR on human hepatocellular carcinoma cell line |
| PP-688 |
SA00923 |
Sarwat Fatima |
The Role of Dickkopf 4 (DKK4) on Wnt Signaling in Hepatocellular Carcinoma |
| PP-689 |
SA00925 |
Xiufeng Chu |
Functional analysis of FBX4 C80G polymorphism and splicing variants in Chinese HCC and ESCC patients |
| PP-690 |
SA00981 |
Suzhen Jiang |
Effects of Hepatitis B Virus S Promoter Deletion in Hepatoma Cell Lines in Vitro |
| PP-691 |
SA00985 |
A Singh |
Cyclooxygenase-2 (COX-2) Expression as a useful tool in the Prognosis of Progressing Liver Disease from Hepatitis to Hepatocellular Carcinoma (HCC) |
| PP-692 |
SA01011 |
Chi-Tan Hu |
An efficient direct tumor injection method in mice to induce intrahepatic metastasis |
| PP-693 |
SA01076 |
Qiang Chen |
Transcriptional coactivator AIB1 promotes human hepatocellular carcinoma progression by enhancing cell proliferation and invasiveness |
| PP-694 |
SA01135 |
Lin Yang |
Small interfering RNA targeting hepatitis B virus X and 5-Aza-dC inhibit growth of hepatocellular carcinoma cells in vivo by reversing p16 hypermethylation and inducing p16 expression |
| PP-695 |
SA01215 |
Mengsen Li |
α-fetoprotein is a novel inhibitor of RAR-β for regulating the expression of CXCR4 in hepatoma cells |
| PP-696 |
SA01240 |
SATENDRA KUMAR NIRALA |
Tunneling Nanotubes: The Novel Conduit for Intercellular Communication and Promising Target for Anti-Cancer Therapies |
| PP-697 |
SA01245 |
Chaoqun Li |
Inhibition of Caspase-12 expression by silencing human androgen receptor expression in HepG2 cells |
| PP-698 |
SA01360 |
Pu-jun Gao |
A positive effect of beta2-GPI in the development of hepatocellular carcinoma |
| PP-699 |
SA01384 |
R.P Gao |
Expression and significance of connective tissue growth factor in human hepatocellular carcinoma |
| PP-700 |
SA01398 |
Tingbo Liang |
Rapamycin, a mTOR inhibitor, prevents hepatocellular carcinoma development in the DEN induce rat |
| PP-701 |
SA01452 |
Yongfeng Wang |
Aberrant miR-9-1 hypermethylation plays a role in HCC |
| PP-702 |
SA01693 |
Sandy Leung Kuen Au |
Frequent upregulation of Enhancer of Zeste Homolog 2 was implicated in Deleted in Liver Cancer 1 gene silencing and HCC progression |
| PP-703 |
SA01715 |
Dinesh Mani Tripathi |
ROLE OF Wnt/ β-CATENIN IN PROGRESSION OF ALCOHOLIC LIVER CIRRHOSIS AND RELATED HEPATOCELLULAR CARCINOMA |
| PP-704 |
SA01773 |
Natalia Pediconi |
TRANSCRIPTIONAL REGULATION OF miR-122 |
| PP-705 |
SA00080 |
CHEN Nai-Ling |
Expressions and clinical significances of apoptosis proteins caspase 8, Bid, Bax, Cytochrome-c, caspase 9 and Bcl-2 in primary hepatic carcinoma |
| PP-706 |
SA00163 |
Zhang Peiyi |
Clinical study of relationship between expression of PTEN and ERK2 in hepatocellular Ccarcinoma. |
| PP-707 |
SA00934 |
Ming-Tzung Lin |
The diagnostic sensitivity of AASLD guideline on hepatocellular carcinoma and it’s application on non-cirrhotic patients |
| PP-708 |
SA00952 |
Hong Zang |
Expression of CAS in hepatocellular carcinoma tissues and its relationship with HBV infection |
| PP-709 |
SA01181 |
Hua Yang |
LAPTM4B-35 Combined with ASS as a Novel Prognostic Biomarker for Hepatocellular Carcinoma Patients after Hepatectomy |
| PP-710 |
SA01286 |
Dong Qiong Zhu |
Upregulation of Osteopontin Encourages Tumor Growth and Metastasis of Human Hepatocellular Carcinoma |
| PP-711 |
SA01287 |
Zhang Xiao Fei |
PARs are not related to the effect that thrombin mediates overall survival and recurrence of HCC patient who underwent primary and curative resection |
| PP-712 |
SA01499 |
Zhu Wen Wei |
The Functional Role of Metastasis-Favoring Gene GOLM-1 in Heptocelluar Carcinoma |
| PP-713 |
SA01504 |
Do Young Kim Kim |
Can combined measurement of AFP and PIVKA-II improve the performance of HCC surveillance? - A prospective randomized study |
| PP-714 |
SA01664 |
Myeong Jun Song |
Usefulness of prediction of treatment response by 18F-FDG PET for Hepatocellular carcinoma |
| PP-715 |
Offline
1 |
Balkrishan Sharma |
Comparison of 7 staging systems in North Indian cohort of Hepatocellular Carcinoma |
| PP-716 |
SA00211 |
Zakia Abdelrahman |
Evaluation of Hepatocyte Growth Factor (HGF) and Interlukin-1 beta (IL-1β) in Patients with Hepatitis C virus infection
(HCV) and Hepatocellular Carcinoma (HCC) |
| PP-717 |
SA00389 |
Jyotdeep Kaur |
Role of promoter region methylation of tumor suppressor genes and oncogenes in hepatitis virus-related hepatocellular carcinoma in India |
| PP-718 |
SA00469 |
Seong Woo Nam |
Efficacy of Tumor markers for early detection of metastasis in patients with hepatocellular carcinoma |
| PP-719 |
SA00552 |
Mitsuaki Sato |
Judgement of biological malingnant potential by combination diagnosis of Gd-EOB-DTPA MRI and Sonazoid-contrast enchanced ultrasonography in hepatocellular carcinoma |
| PP-720 |
SA00752 |
Peng Li |
Evaluation of diagnostic value of sera AFP for primary hepatocellular carcinoma |
| PP-721 |
SA00775 |
Ali Nada |
AFPL3% Versus AFP in diagnosis of HCC in Egyptian patients |
| PP-722 |
SA00822 |
Yunpeng Zhao |
Assessment of serum N-glycans marker in HBV-related hepatocellular carcinoma follow-up study |
| PP-723 |
SA01110 |
A.Kadir Dokmeci |
Diagnostic value of Lectin-reactive alpha-fetoprotein (AFP-L3) and des-gamma-carboxy prothrombin (DCP) for Hepatocellular Carcinoma (HCC): First study with a Turkish patient cohort |
| PP-724 |
SA01140 |
Shintaro Kikkawa |
Early diagnosis of hepatocellular carcinoma using the new generation of high-sensitve lens culinaris agglutinin-reactive fraction of alpha-fetoprotein assay |
| PP-725 |
SA01216 |
Sirong Chen |
Bone as the First Site of Metastasis from Hepatocellular Carcinoma – Detection and Analysis by Dual-Tracer PET/CT |
| PP-726 |
SA01295 |
Dai Chun |
Oct4, an embryonic stem cell marker, promoting cell proliferation and metastasis is an oncogene in Hepatocelluar carcinoma |
| PP-727 |
SA01603 |
Rongxin Chen |
Osteopontin, a single marker for predicting the prognosis of patients with the tumor-node-metastasis (TNM) stage I hepatocellular carcinoma after surgical resection |
| PP-728 |
SA01672 |
Zhen Zeng |
Up-regulation of PD-1/PD-L1 in peripheral blood mononuclear cells predicts poor prognosis in HBV-related hepatocellular carcinoma patients |
| PP-729 |
SA01811 |
Qing Wang |
Detection of the altered expression of DDAH-1 in hepatocellular carcinoma by using laser capture microdissection and proteome analysis |
| PP-730 |
SA01214 |
Jun-liang Fu |
Increased FoxP3+ regulatory T cells are associated with tumor metastasis and poor survival in hepatocellular carcinoma patients |
| PP-731 |
SA01258 |
Zhi Du |
Association of the single nucleotide polymorphism of IL-10 and ALDH2 with hepatocellular carcinoma |
| PP-732 |
SA01551 |
Ha Na Park |
Hepatocellular carcinoma in Budd-Chiari syndrome: a single center experience in Korea |
| PP-733 |
Offline 2 |
Balkrishan Sharma |
Changing etiology of hepatocellular carcinoma in North Indian HCC patients |
| PP-734 |
SA00119 |
Takamasa Ohki |
Metabolic syndrome is an independent risk factor of hepatocellular carcinoma recurrence after curative treatment in non-B non-C chronic liver disease patients |
| PP-735 |
SA00256 |
Nalani Grace |
Family history does not affect survival from hepatocellular carcinoma |
| PP-736 |
SA00446 |
Fen Jiang MD PHD |
African-American Ethnicity, Filipino Ethnicity, and Low SES are Independent Unfavorable Prognostic Factors for Overall Survival in Hepatocellular Cancer |
| PP-737 |
SA00646 |
Xiangmei Chen |
Association of TNF-a gene polymorphisms with risk of hepatitis B-related hepatocellular carcinoma in Chinese population |
| PP-738 |
SA01106 |
A.Kadir Dokmeci |
Characteristics of hepatocelluler carcinoma in Turkey |
| PP-739 |
SA01197 |
Feng Shi |
PD-1 and PD-L1 upregulation promotes tumor evasion of immune control in hepatocellular carcinoma patients |
| PP-740 |
SA01304 |
Hong-Xing Wu |
Hepatocellular Carcinoma Mortality in Canada from 1980 to 2004 |
| PP-741 |
SA01436 |
SHYAM KOTTILIL |
Screening for HCC in India: Early Detection and Impact on Survival. |
| PP-742 |
SA01630 |
Suwandhi Widjaja |
Changing of HCC profile in the last decade at Medistra Hospital |
| PP-743 |
SA00621 |
Guohong Han |
Transarterial chemoembolization in combination with sorafenib for advanced hepatocellular carcinoma in hepatitis B–endemic Asian population |
| PP-744 |
SA00708 |
Sung Bum Cho |
Comparsion of sorafenib and radiotherapy in unresectable hepatocellular carcinoma patients whom transcatheter arterial chemoembolization was ineffective or unsuitable |
| PP-745 |
SA00757 |
Gerby Coronel |
Transarterial Chemoembolization for hepatocellular carcinoma: Long term outcome and Prognostic factors affecting survival |
| PP-746 |
SA00794 |
Jeong-Hoon Lee |
Transarterial chemoembolization significantly improves the overall survival in patients with hepatocellular carcinoma invading main portal vein |
| PP-747 |
SA00832 |
Esperanza Grace Santi |
Major Complications of Percutaneous Radiofrequency Ablation (RFA) are Associated with the Number of RFA Zones Created: A Caution on Trying to Do Too Much |
| PP-748 |
SA00891 |
Ming Kuang |
Ethanol Ablation Of Hepatocellular Carcinoma Sized Up To 5 cm By Using A Multi-pronged Injection Needle With High-Dose Strategy |
| PP-749 |
SA00905 |
Soon Sun Kim |
Comparison of Radiofrequency Ablation and Transarterial Chemoembolization for Treatment of Single Hepatocellular Carcinoma Smaller Than 4 cm |
| PP-750 |
SA01020 |
Zhen-Wei Peng |
A Prospective Study on Radiofrequency Ablation Versus Surgical Resection for Small Solitary Hepatocellular Carcinoma |
| PP-751 |
SA01204 |
Teh-Ia Huo |
Transarterial chemoembolization in patients with hepatocellular carcinoma and renal insufficiency |
| PP-752 |
SA01266 |
Kyung In Lee |
The Comparison of Treatment Efficacy Between Concurrent Chemoradiotherapy and Hepatic Arterial Infusion Therapy in Advanced Hepatocellular Carcinoma |
| PP-753 |
SA01606 |
Sehun Kang |
Comparing the outcomes of transarterial chemoembolization and hepatic resection in patients with single hepatocellular carcinoma less than 3 cm |
| PP-754 |
SA00526 |
Kazuhiro Kasai |
Evaluation of newly developed combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion |
| PP-755 |
SA00660 |
Won Hyeok Choe |
Sorafenib combined with transarterial-chemoembolization for unresectable hepatocellular carcinoma: Focusing on side-effects during early-phases of treatment |
| PP-756 |
SA00872 |
Seul Ki Min |
The Comparison of Effects between Concurrent Chemoradiation Therapy and Hepatic Arterial Infusion Chemotherapy using 5-fluorouracil, cisplatin and doxorubicin for Unresectable Hepatocellular Carcinoma |
| PP-757 |
SA00343 |
Fumihiko Kanai |
Assessment of predictive biological markers with an oral angiogenic receptor tyrosine kinase inhibitor, TSU-68, in the phase I/II study for advanced hepatocellular carcinoma |
| PP-758 |
SA00776 |
Yuqin Li |
Immunological Effects of a Recombinant Genetic Vaccine Encoding Hepatocellular Carcinoma (HCC) Antigen HCA661 and Mycobacterium Tuberculosis heat shock protein 70 C-terminal stimulatory domain fusion protein |
| PP-759 |
SA01024 |
Shuntaro Obi |
Combination therapy of intra-arterial 5-FU and systemic IFN for advanced hepatocellular carcinoma with portal venous invasion. |
| PP-760 |
SA01510 |
Wei Zhang |
Effects of avastin combined with sorafenib in a highly metastatic murine model of human hepatocellular carcinoma |
| PP-761 |
SA01565 |
Christian Freise |
L.obtusiloba exerts anti-mitogenic effects and decreases expression of pro-angiogenic HIF-1α and tumor-elevated PPARγ and COX-2 in human hepatocellular carcinoma cell lines |
| PP-762 |
SA01575 |
Rajan Somasundaram |
Intermediate conductance calcium-activated potassium channel (IKCa) as target for anti-neoplastic treatments: specific IKCa blocker TRAM-34 in HCC blocks in vitro invasion and migration |
| PP-763 |
SA01601 |
Su Cheol Park |
Silibinin enhances the growth inhibitory effects of gefitinib in hepatocellular carcinoma |
| PP-764 |
SA01649 |
Xiao-Dong Zhu |
Evaluating antiangiogenic effects of pazopanib (GW786034B) in hepatocellular carcinoma xenograft models by quantitative contrast-enhanced ultrasonography |
| PP-765 |
SA00531 |
Naruhiko Nagata |
Two years of TAE experience in Tokai University hospital |
| PP-766 |
SA00566 |
Paolo Villareal |
Radiofrequency Ablation Combined with Hypertonic Saline: An Ex Vivo Study in Bovine Liver |
| PP-767 |
SA00614 |
Nam Hwan Park |
A Case of Complete Response After Transaterial Chemoembolization and Radiotherapy for Portal Vein Malignant Thrombus in Patient With Unresectable Hepatocellular Carcinoma |
| PP-768 |
SA00615 |
Alexander Kabakov |
Hsp27 phosphorylation can enhance radioresistance of hepatocarcinoma cells by stimulating Akt activation |
| PP-769 |
SA01610 |
Chinburen Jigjidsuren |
Introduction of RFA in Mongolia: year 1 treatment results at National Cancer Center of Mongolia. |
| PP-770 |
SA00528 |
Noriyuki Oba |
Hepatic Resection for Hepatocellular Carcinoma with an Involvement of Inferior Vena Cava |
| PP-771 |
SA01609 |
Woo Young Shin |
Hepatic resection for hepatocellular carcinoma with portal vein invasion |
| PP-772 |
SA01679 |
Jeong Won Jang |
Effect of hepatitis B viral status on cancer recurrence and long-term prognosis after surgical resection in patients with hepatocellular carcinoma |
| PP-773 |
SA00157 |
Markiyan Soloviy |
LAPAROSCOPIC VERSUS OPEN HEPATECTOMY – A META-ANALYSIS. |
| PP-774 |
SA00192 |
Joji Yamamoto |
Anterior approach for a huge hepatocellular carcinoma |
| PP-775 |
SA00305 |
Chien-Wei Su |
Minimal Fibrosis and Lower Aspartate Aminotransferase-Platelet Ratio Index Is Associated With Better Prognosis for Patients With Small Solitary Hepatitis-B Virus related Hepatocellular Carcinoma Underwent Resection Surgery |
| PP-776 |
SA00593 |
Byung Seok Lee |
A Case of Ruptured Hepatocellular Carcinoma, Treated by Two Staged Operation |
| PP-777 |
SA00714 |
Chinburen Jigjidsuren |
Surgical Treatment Outcomes for Liver Cancer Patients at the National Cancer Center (NCC) of Mongolia |
| PP-778 |
SA00779 |
Thomas Decaens |
AFP level is a simple test for a reasonable expansion of Milan criteria for liver transplantation for hepatocellular carcinoma |
| PP-779 |
SA01010 |
Tian Yang |
Viral load is associated with long-term survival after curative resection of hepatitis B virus-related hepatocellular carcinoma: a prospective cohort study |
| PP-780 |
SA01305 |
Hong-Guang Wang |
Robotic-Assisted Laparoscopic Anatomic Hepatectomy in China: Initial Experience |
| PP-781 |
SA01593 |
Woo Young Shin |
Prognostic role of preoperative radiologic morphology of huge (≥10cm) hepatocellular carcinoma |
| PP-782 |
SA01596 |
Kyung-Suk Suh |
RECENT IMPROVEMENT OF OUTCOME OF HEPATIC RESECTION FOR HEPATOCELLULAR CARCINOMA |
| PP-783 |
SA00155 |
Eun Ju Cho |
Protein disulfide isomerase inhibition potentiates hexokinase II inhibitor-induced hepatocellular carcinoma cell death by augmenting ER stress |
| PP-784 |
SA01673 |
Tae Hyo Kim |
Clinical characteristics of hepatocellular carcinoma developed in the patients with chronic hepatitis B undergoing antiviral therapy |
| PP-785 |
SA00129 |
Ayesha Baig |
LEVEL OF ALPHA-FETPPROTEIN IN DIABETIC PATEINT HAVING HEPATOCELLULAR CARCINOMA |
| PP-786 |
SA00666 |
Su Jong Yu |
Hepatocellular Carcinoma with Bile Duct Invasion: Survival and Prognostic Factors in Inoperable Cases |
| PP-787 |
SA00871 |
Jae Young Jang |
The analysis of variceal hemorrhage in the patients with hepatocelluar carcinoma |
| PP-788 |
SA01060 |
Zaigham Abbas |
Hepatocellular carcinoma in HDV: Does it differ from HBV monoinfection |
| PP-789 |
SA01108 |
A.Kadir Dokmeci |
Comparison of therapeutic effects between percutaneous ethanol injection therapy and radiofrequency ablation for hepatocellular carcinoma |
| PP-790 |
SA01137 |
Yunhong Xia |
Inhibition of T-Cell Responses by Intratumoral Hepatic Stellate Cells Contribute to Migration and Invasion of Hepatocellular Carcinoma |
| PP-791 |
SA01219 |
Sirong Chen |
Characteristics of Bone Metastasis as the Only Site of Metastasis are Different from Those of Being Part of Multi-Organ Metastases in Hepatocellular Carcinoma |
| PP-792 |
SA01236 |
Young Eun Chon |
Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: Endoscopic findings and risk factors |
| PP-793 |
SA01361 |
Pu-jun Gao |
Beta2-GPI: a possible factor in the development of hepatocellular carcinoma |
| PP-794 |
SA01422 |
Xiaoyan Xie |
Ablation Therapy with Real-Time Virtual System for Treating Malignant Liver Tumo |
| PP-795 |
SA01455 |
Yun Deng |
Epigenetic silencing of WIF-1 in hepatocellular carcinomas |
| PP-796 |
SA01465 |
Carmen W.H. Chan |
The effects of palliative treatment modalities of Hepatocellular Carcinoma (HCC) on Patients' quality of life |
| PP-797 |
SA01695 |
Izumi Kirino |
Management of Spontaneously Ruptured Hepatocellular carcinoma: 15-year Experience in a single institution. |
| PP-798 |
SA01783 |
Cong Wen-Ming* |
Small hepatocellular carcinoma of 3 cm or less in diameter is a predictor of biological behavior |